Document:

<PAGE>

                                                                    EXHIBIT 10.6
Agreement and Plan of Merger by and amount Halis, Inc., HealthWatch Merger Sub,
Inc. and HealthWatch, Inc. dated June 29, 2000

                         AGREEMENT AND PLAN OF MERGER

                                 BY AND AMONG

                                 HALIS, INC.,

                         HEALTHWATCH MERGER SUB, INC.

                                      AND

                               HEALTHWATCH, INC.

                           DATED AS OF JUNE 29, 2000
<PAGE>

                               TABLE OF CONTENTS
<TABLE>
<CAPTION>

<S>                                                                         <C>
ARTICLE I
 THE MERGER................................................................  2
 SECTION 1.1 THE MERGER....................................................  2
 SECTION 1.2 CLOSING.......................................................  2
 SECTION 1.3 EFFECTIVE TIME................................................  2
 SECTION 1.4 EFFECTS OF THE MERGER.........................................  2
 SECTION 1.5 CERTIFICATE OF INCORPORATION AND BY-LAWS OF THE SURVIVING
     CORPORATION AND HEALTHWATCH...........................................  2
 SECTION 1.6 DIRECTORS AND OFFICERS........................................  2

ARTICLE II
 EFFECT OF THE MERGER ON THE CAPITAL STOCK
 OF THE CONSTITUENT CORPORATIONS;
 EXCHANGE OF CERTIFICATES..................................................  2
 SECTION 2.1 EFFECT ON CAPITAL STOCK.......................................  2
      (a) CANCELLATION OF TREASURY STOCK AND HEALTHWATCH-OWNED STOCK.......  3
      (b) CONVERSION OF HALIS COMMON STOCK.................................  3
      (c) MERGER SUB COMMON STOCK..........................................  3
      (d) HEALTHWATCH COMMON STOCK.........................................  3
      (e) OPTIONS..........................................................  3
 SECTION 2.2 EXCHANGE OF CERTIFICATES......................................  4
      (a) EXCHANGE AGENT...................................................  4
      (b) EXCHANGE PROCEDURES..............................................  4
      (c) DISTRIBUTIONS WITH RESPECT TO UNEXCHANGED SHARES.................  5
      (d) NO FURTHER OWNERSHIP RIGHTS IN HALIS COMMON STOCK................  5
      (e) NO FRACTIONAL SHARES.............................................  5
      (f) TERMINATION OF EXCHANGE FUND.....................................  5
      (g) NO LIABILITY.....................................................  6
      (h) INVESTMENT OF EXCHANGE FUND......................................  6
      (i) LOST CERTIFICATES................................................  6
      (j) HALIS DISSENTING SHARES..........................................  6
 SECTION 2.3 CERTAIN ADJUSTMENTS...........................................  6

ARTICLE III
 REPRESENTATIONS AND WARRANTIES............................................  6
 SECTION 3.1 REPRESENTATIONS AND WARRANTIES OF HEALTHWATCH AND MERGER SUB..  6
      (a) ORGANIZATION, STANDING AND CORPORATE POWER.......................  7
      (b) SUBSIDIARIES.....................................................  7
      (c) CAPITAL STRUCTURE................................................  7
      (d) AUTHORITY; NONCONTRAVENTION......................................  8
      (e) SEC DOCUMENTS; UNDISCLOSED LIABILITIES........................... 10
      (f) INFORMATION SUPPLIED............................................. 10
      (g) ABSENCE OF CERTAIN CHANGES OR EVENTS............................. 10
      (h) COMPLIANCE WITH APPLICABLE LAWS; LITIGATION...................... 11
      (i) ABSENCE OF CHANGES IN BENEFIT PLANS.............................. 12
      (j) BENEFIT PLANS.................................................... 12
      (k) TAXES............................................................ 13
</TABLE>
                                    Page i
<PAGE>

<TABLE>
<CAPTION>

<S>                                                                         <C>
      (l) VOTING REQUIREMENTS.............................................. 14
      (m) STATE TAKEOVER STATUTES.......................................... 14
      (n) BROKERS.......................................................... 14
      (o) INTELLECTUAL PROPERTY............................................ 14
      (p) CERTAIN CONTRACTS................................................ 16
      (q) ENVIRONMENTAL LIABILITY.......................................... 17
      (r) INSURANCE........................................................ 17
      (s) TRANSACTIONS WITH AFFILIATES..................................... 17
      (t) FULL DISCLOSURE.................................................. 17
 SECTION 3.2 REPRESENTATIONS AND WARRANTIES OF HALIS....................... 17
      (a) ORGANIZATION, STANDING AND CORPORATE POWER....................... 17
      (b) SUBSIDIARIES..................................................... 18
      (c) CAPITAL STRUCTURE................................................ 18
      (d) AUTHORITY; NONCONTRAVENTION...................................... 19
      (e) SEC DOCUMENTS; UNDISCLOSED LIABILITIES........................... 20
      (f) INFORMATION SUPPLIED............................................. 20
      (g) ABSENCE OF CERTAIN CHANGES OR EVENTS............................. 21
      (h) COMPLIANCE WITH APPLICABLE LAWS; LITIGATION...................... 21
      (i) ABSENCE OF CHANGES IN BENEFIT PLANS.............................. 22
      (j) BENEFIT PLANS.................................................... 22
      (k) TAXES............................................................ 23
      (l) VOTING REQUIREMENTS.............................................. 24
      (m) STATE TAKEOVER STATUTES.......................................... 24
      (n) BROKERS.......................................................... 24
      (o) INTELLECTUAL PROPERTY............................................ 24
      (p) CERTAIN CONTRACTS................................................ 26
      (q) ENVIRONMENTAL LIABILITY.......................................... 26
      (r) INSURANCE........................................................ 26
      (s) TRANSACTIONS WITH AFFILIATES..................................... 27
      (t) FULL DISCLOSURE.................................................. 27

ARTICLE IV
 COVENANTS RELATING TO CONDUCT OF BUSINESS................................. 27
 SECTION 4.1 CONDUCT OF BUSINESS........................................... 27
      (a) CONDUCT OF BUSINESS BY HEALTHWATCH............................... 27
      (b) CONDUCT OF BUSINESS BY HALIS..................................... 27
      (c) OTHER ACTIONS.................................................... 27
      (d) ADVISE OF CHANGES................................................ 28
 SECTION 4.2 NO SOLICITATION BY HALIS...................................... 28
 SECTION 4.3 HEALTHWATCH PRIVATE PLACEMENT................................. 30

ARTICLE V
 ADDITIONAL AGREEMENTS..................................................... 30
 SECTION 5.1 PREPARATION OF THE FORM S-4 AND THE JOINT PROXY STATEMENT;
      STOCKHOLDERS' MEETINGS............................................... 30
 SECTION 5.2 LETTERS OF HEALTHWATCH'S ACCOUNTANTS.......................... 31
 SECTION 5.3 LETTERS OF HALIS' ACCOUNTANTS................................. 31
 SECTION 5.4 ACCESS TO INFORMATION; CONFIDENTIALITY........................ 31
 SECTION 5.5 COMMERCIALLY REASONABLE EFFORTS............................... 32
 SECTION 5.6 INDEMNIFICATION, EXCULPATION AND INSURANCE.................... 32
 SECTION 5.7 FEES AND EXPENSES............................................. 33
</TABLE>

                                    Page ii
<PAGE>

 SECTION 5.8 PUBLIC ANNOUNCEMENTS.......................................... 33
 SECTION 5.9 AFFILIATES.................................................... 33
 SECTION 5.10  NASDAQ...................................................... 33
 SECTION 5.11 TAX TREATMENT................................................ 34
 SECTION 5.12 EMPLOYEE BENEFITS............................................ 34
 SECTION 5.13 LOCK-UP...................................................... 34

ARTICLE VI
 CONDITIONS PRECEDENT...................................................... 34
 SECTION 6.1 CONDITIONS TO EACH PARTY'S OBLIGATION TO EFFECT THE MERGER.... 34
      (a) STOCKHOLDER APPROVALS............................................ 34
      (b) GOVERNMENTAL, REGULATORY AND OTHER APPROVALS..................... 34
      (c) NO INJUNCTIONS OR RESTRAINTS..................................... 34
      (d) FORM S-4......................................................... 35
      (e) NASDAQ LISTINGS.................................................. 35
      (f) TAX OPINIONS..................................................... 35
      (g) OPINION OF FINANCIAL ADVISORS.................................... 35
      (h) OPINION OF FINANCIAL ADVISORS.................................... 35
      (i) LOCKUP AGREEMENTS................................................ 35
 SECTION 6.2 CONDITIONS TO OBLIGATIONS OF HALIS............................ 35
      (a) REPRESENTATIONS AND WARRANTIES................................... 35
      (b) PERFORMANCE OF OBLIGATIONS OF HEALTHWATCH........................ 36
      (c) NO MATERIAL ADVERSE CHANGE....................................... 36
 SECTION 6.3 CONDITIONS TO OBLIGATIONS OF HEALTHWATCH...................... 36
      (a) REPRESENTATIONS AND WARRANTIES................................... 36
      (b) PERFORMANCE OF OBLIGATIONS OF HALIS.............................. 36
      (c) NO MATERIAL ADVERSE CHANGE....................................... 36

ARTICLE VII
 TERMINATION, AMENDMENT AND WAIVER......................................... 36
 SECTION 7.1 TERMINATION................................................... 36
 SECTION 7.2 EFFECT OF TERMINATION......................................... 37
 SECTION 7.3 AMENDMENT..................................................... 38
 SECTION 7.4 EXTENSION; WAIVER............................................. 38

ARTICLE VIII
 GENERAL PROVISIONS........................................................ 39
 SECTION 8.1 NONSURVIVAL OF REPRESENTATIONS AND WARRANTIES................. 39
 SECTION 8.2 NOTICES....................................................... 39
 SECTION 8.3 DEFINITIONS................................................... 39
 SECTION 8.4 INTERPRETATION................................................ 40
 SECTION 8.5 COUNTERPARTS.................................................. 40
 SECTION 8.6 ENTIRE AGREEMENT; NO THIRD-PARTY BENEFICIARIES................ 41
 SECTION 8.7 GOVERNING LAW................................................. 41
 SECTION 8.8 ASSIGNMENT.................................................... 41
 SECTION 8.9 CONSENT TO JURISDICTION....................................... 41
 SECTION 8.10 HEADINGS, ETC................................................ 41
 SECTION 8.11 SEVERABILITY................................................. 41
 SECTION 8.12 DISCLOSURE SCHEDULES......................................... 41

                                   Page iii
<PAGE>

                                   EXHIBITS

EXHIBIT A HealthWatch Stock Plans
EXHIBIT B Halis Stock Plans
EXHIBIT C Form of Rule 145 Letter

                                    Page iv
<PAGE>

  AGREEMENT AND PLAN OF MERGER dated as of June 29th, 2000 among HEALTHWATCH,
INC., a Minnesota corporation ("HealthWatch"), HALIS, INC., a Georgia
corporation ("Halis") and HEALTHWATCH MERGER SUB, INC. ("Merger Sub"), a Georgia
corporation and a wholly-owned subsidiary of HEALTHWATCH.

                                 WITNESSETH:

  WHEREAS, the respective Boards of Directors of Halis, Merger Sub and
HealthWatch have each approved the merger of Halis with and into Merger Sub (the
"Merger"), upon the terms and subject to the conditions set forth in this
Agreement, whereby each issued and outstanding share of common stock, par value
$.01 per share, of Halis ("Halis Common Stock"), other than shares owned by
Halis or HealthWatch, will be converted into the right to receive the Merger
Consideration (as defined in Section 2.1(b)); and

  WHEREAS, the respective Boards of Directors of Halis and HealthWatch, having
carefully considered the long-term prospects and interests of Halis and
HealthWatch and their respective stockholders and having determined that the
Merger and the other transactions contemplated hereby are consistent with, and
in furtherance of, their respective business strategies and goals and are
advisable and in the best interests of their respective stockholders, have each
approved the transactions contemplated by this Agreement and have each resolved
to recommend to each party's stockholders the approval and adoption of this
Agreement and the Merger and the consummation of the transactions contemplated
hereby and thereby upon the terms and subject to the conditions set forth
herein; and

  WHEREAS, for federal income tax purposes, it is intended that the Merger will
qualify as a reorganization under the provisions of Section 368(a) of the
Internal Revenue Code of 1986, as amended, and the rules and regulations
promulgated thereunder (the "Code"), and this Agreement is intended to be and is
adopted as a plan of reorganization within the meaning of Section 368 of the
Code; and

  WHEREAS, Halis and HealthWatch desire to make certain representations,
warranties, covenants and agreements in connection with the Merger and also to
prescribe various conditions to the Merger.

  NOW, THEREFORE, in consideration of the representations, warranties, covenants
and agreements set forth herein, the parties agree as follows:
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                          Page 2

                                   ARTICLE I

                                  THE MERGER

  SECTION 1.1 THE MERGER. Upon the terms and subject to the conditions set forth
in this Agreement, Halis shall be merged with and into Merger Sub at the
Effective Time (as defined in Section 1.3). Following the Effective Time, the
separate corporate existence of Halis shall cease and Merger Sub shall be the
surviving corporation (the "Surviving Corporation") and shall succeed to and
assume all the rights and obligations of Halis.

  SECTION 1.2 CLOSING. The closing of the Merger (the "Closing") will take place
on a date to be specified by the parties (the "Closing Date"), which shall be no
later than the second business day after satisfaction or waiver of the
conditions set forth in Article VI, unless another time or date is agreed to by
the parties hereto. The Closing will be held at the offices of Gambrell & Stolz,
L.L.P., Suntrust Plaza, Suite 4300, 303 Peachtree Street, N.E. Atlanta, Georgia
30308.

  SECTION 1.3 EFFECTIVE TIME. Subject to the provisions of this Agreement, on
the Closing Date, the parties shall cause the Merger to be consummated by filing
a certificate of merger or other appropriate documents (in any such case, the
"Certificate of Merger") executed in accordance with the relevant provisions of
Georgia law and shall make all other filings or recordings required. The Merger
shall become effective at such time as the Certificate of Merger is duly filed
with the Secretary of State of the State of Georgia, or at such subsequent date
or time as Halis, Merger Sub and HealthWatch shall agree and specify in the
Certificate of Merger (the time the Merger becomes effective being hereinafter
referred to as the "Effective Time").

  SECTION 1.4 EFFECTS OF THE MERGER. At the Effective Time of the Merger, the
separate existence of Halis shall cease and Halis shall be merged with and into
Merger Sub. The Merger shall have the effects set forth in Section 14-2-1106 et
seq. of the Official Code of Georgia Annotated. In addition, the Surviving
Corporation may, at any time after the Effective Time, take any actions
(including executing and delivering any document) in the name and on behalf of
either HealthWatch or Halis in order to carry out and effectuate the
transactions contemplated by this Agreement.

  SECTION 1.5 ARTICLES OF INCORPORATION AND BY-LAWS OF THE SURVIVING CORPORATION
AND HEALTHWATCH. At the Effective Time, the Articles of Incorporation and the
by-laws of Merger Sub, as in effect immediately prior to the Effective Time,
shall be the Articles of Incorporation and by-laws of the Surviving Corporation,
in each case until thereafter amended in accordance with applicable law.

  SECTION 1.6 DIRECTORS AND OFFICERS. The directors of Merger Sub and the
officers of Merger Sub shall retain their respective positions and terms of
office in the Surviving Corporation, and will hold office in accordance with the
Articles of Incorporation and By-Laws of the Surviving Corporation.

                                  ARTICLE II
                   EFFECT OF THE MERGER ON THE CAPITAL STOCK
                       OF THE CONSTITUENT CORPORATIONS;
                           EXCHANGE OF CERTIFICATES

  SECTION 2.1 EFFECT ON CAPITAL STOCK. As of the Effective Time, by virtue of
the Merger and without any action on the part of HealthWatch, Merger Sub, Halis
or the holder of any shares of the following securities:
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                          Page 3

  (a) CANCELLATION OF TREASURY STOCK AND HEALTHWATCH-OWNED STOCK. Each share of
Halis Common Stock that is owned by HealthWatch, or is held by Halis as treasury
stock, shall automatically be canceled and retired and shall cease to exist, and
no consideration shall be delivered in exchange therefor.

  (b) CONVERSION OF HALIS COMMON STOCK. Subject to Section 2.2(e), each issued
and outstanding share of Halis Common Stock (other than shares to be canceled in
accordance with Section 2.1(a)) shall be converted into the right to receive one
twentieth (.050) of a share of the fully paid and nonassessable common stock,
$.05 par value, of HealthWatch ("HealthWatch Common Stock")("Merger
Consideration"; the "Exchange Ratio" shall be one share of HealthWatch Common
Stock for twenty shares of Halis Common Stock, or .050).  As of the Effective
Time, all such shares of Halis Common Stock shall no longer be outstanding and
shall automatically be canceled and retired and shall cease to exist, and each
holder of a certificate representing any such shares of Halis Common Stock shall
cease to have any rights with respect thereto, except the right to receive the
Merger Consideration and any cash in lieu of fractional shares of HealthWatch
Common Stock to be issued or paid in consideration thereof upon surrender of
each such certificate in accordance with Section 2.2(e).

  (c) MERGER SUB COMMON STOCK. At and after the Effective Time, each share of
common stock, no par value, of Merger Sub ("Merger Sub Common Stock") shall
remain an issued and outstanding share of common stock of Merger Sub and shall
not be affected by the Merger (Merger Sub shall continue to be wholly-owned by
HealthWatch).

  (d) HEALTHWATCH COMMON STOCK. At and after the Effective Time, each share of
HealthWatch Common Stock issued and outstanding immediately prior to the Closing
Date shall remain an issued and outstanding share of common stock of HealthWatch
and shall not be affected by the Merger.

 (e) OPTIONS.

     (i) Halis and HealthWatch shall take all action necessary such that, at the
Effective Time, each option or warrant granted by Halis to purchase shares of
Halis Common Stock which is outstanding immediately prior thereto shall cease to
represent a right to acquire shares of Halis Common Stock and shall be converted
into an option to purchase shares of HealthWatch Common Stock in an amount and
at an exercise price determined as provided below (and otherwise, in the case of
options, subject to the terms of the Halis Stock Plans (as defined in Section
3.2(c)) and the agreements evidencing grants thereunder) (the "Assumed
Options"):

          (1) The number of shares of HealthWatch Common Stock to be subject to
the new option or warrant shall be equal to the product of the number of shares
of Halis Common  Stock subject to the original option and the Exchange Ratio,
provided that any fractional shares of HealthWatch Common Stock resulting from
such multiplication shall be rounded up or down to the nearest whole share; and

          (2) The exercise price per share of HealthWatch Common Stock under the
new option shall be equal to the exercise price per share of Halis Common Stock
under the original option divided by the Exchange Ratio, provided that such
exercise price shall be rounded up or down to the nearest whole cent.

     (ii) The duration and other terms of the new options shall be the same as
the original options except that all references to Halis shall be deemed to be
references to HealthWatch.

     (iii) As soon as practicable following the Effective Time, HealthWatch
shall deliver, upon due surrender of the Assumed Options to HealthWatch,
appropriate option agreements representing the right to acquire HealthWatch
Common Stock on the same terms and conditions as contained in the Assumed
Options (except as otherwise set forth in this Section 2.1(e)). Except as
expressly contemplated herein, HealthWatch
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                          Page 4

shall comply with the terms of the Halis Stock Plans as they apply to the
Assumed Options. HealthWatch shall take all corporate action necessary to
reserve for issuance a sufficient number of shares of HealthWatch Common Stock
for delivery upon exercise of the Assumed Options in accordance with this
Section 2.1(e). HealthWatch shall file a registration statement on Form S-8 (or
any successor form) or on another appropriate form, and use commercially
reasonable efforts to have such registration statement declared effective
reasonably promptly following the Effective Time, with respect to HealthWatch
Common Stock subject to the Assumed Options, and shall use commercially
reasonable efforts to maintain the effectiveness of such registration statement
or registration statements (and maintain the current status of the prospectus or
prospectuses contained therein) for so long as the Assumed Options remain
outstanding and exercisable.

     (iv) HealthWatch acknowledges and agrees that the consummation of the
Merger will have certain effects in respect of the Assumed Options as reflected
in Section 3.2(c) of the Halis Disclosure Schedule, and HealthWatch agrees to
act in accordance therewith and give full effect to same.

 SECTION 2.2 EXCHANGE OF CERTIFICATES.

  (a) EXCHANGE AGENT. As of the Effective Time, HealthWatch shall enter into an
agreement with such bank or trust company as may be designated by HealthWatch
(the "Exchange Agent") which shall provide that HealthWatch shall provide
HealthWatch Common Stock (such shares of HealthWatch Common Stock, together with
any dividends or distributions with respect thereto with a record date after the
Effective Time, and any cash payable in lieu of any fractional shares of
HealthWatch Common Stock being hereinafter referred to as the "Exchange Fund")
issuable pursuant to Section 2.1 in exchange for outstanding shares of Halis
Common Stock.

  (b) EXCHANGE PROCEDURES. As soon as reasonably practicable after the Effective
Time, the Exchange Agent shall mail to each holder of record of a certificate or
certificates which immediately prior to the Effective Time represented
outstanding shares of Halis Common Stock (the "Certificates") whose shares were
converted into the right to receive the Merger Consideration pursuant to Section
2.1, (i) a letter of transmittal (which shall specify that delivery shall be
effected, and risk of loss and title to the Certificates shall pass, only upon
delivery of the Certificates to the Exchange Agent, and shall otherwise be in
customary form) and (ii) instructions for use in surrendering the Certificates
in exchange for the Merger Consideration. Upon surrender of a Certificate for
cancellation to the Exchange Agent, together with such letter of transmittal,
duly executed, and such other documents as may reasonably be required by the
Exchange Agent, the holder of such Certificate shall be entitled to receive in
exchange therefor a certificate representing that number of whole shares of
HealthWatch Common Stock which such holder has the right to receive pursuant to
the provisions of this Article II, certain dividends or other distributions in
accordance with Section 2.2(c) and cash in lieu of any fractional share of
HealthWatch Common Stock in accordance with Section 2.2(e), and the Certificate
so surrendered shall forthwith be canceled.  In the event of a surrender of a
Certificate representing shares of Halis Common Stock which are not registered
in the transfer records of Halis under the name of the person surrendering such
Certificate, a certificate representing the proper number of shares of
HealthWatch Common Stock may be issued to a person other than the person in
whose name the Certificate so surrendered is registered if such Certificate
shall be properly endorsed or otherwise be in proper form for transfer and the
person requesting such issuance shall pay any transfer or other taxes required
by reason of the issuance of shares of HealthWatch Common Stock to a person
other than the registered holder of such Certificate or establish to the
satisfaction of HealthWatch that such tax has been paid or is not applicable.
Until surrendered as contemplated by this Section 2.2, each Certificate shall be
deemed at any time after the Effective Time to represent only the right to
receive upon such surrender the Merger Consideration which the holder thereof
has the right to receive in respect of such Certificate pursuant to the
provisions of this Article II, certain dividends or other distributions in
accordance with Section 2.2(c) and cash in lieu of any fractional share of
HealthWatch Common Stock in accordance with Section 2.2(e).  No interest shall
be paid or will accrue on any cash payable to holders of Certificates pursuant
to the provisions of this Article II.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                          Page 5

  (c) DISTRIBUTIONS WITH RESPECT TO UNEXCHANGED SHARES. No dividends or other
distributions with respect to HealthWatch Common Stock with a record date after
the Effective Time shall be paid to the holder of any unsurrendered Certificate
with respect to the shares of HealthWatch Common Stock represented thereby, and,
in the case of Certificates representing Halis Common Stock, no cash payment in
lieu of fractional shares shall be paid to any such holder pursuant to Section
2.2(e), and all such dividends, other distributions and cash in lieu of
fractional shares of HealthWatch Common Stock shall be paid by HealthWatch to
the Exchange Agent and shall be included in the Exchange Fund, in each case
until the surrender of such Certificate in accordance with this Article II.
Subject to the effect of applicable escheat or similar laws, following surrender
of any such Certificate there shall be paid to the holder of the certificate
representing whole shares of HealthWatch Common Stock issued in exchange
therefor, without interest, (i) at the time of such surrender, the amount of
dividends or other distributions with a record date after the Effective Time
theretofore paid with respect to such whole shares of HealthWatch Common Stock
and, in the case of Certificates representing Halis Common Stock, the amount of
any cash payable in lieu of a fractional share of HealthWatch Common Stock to
which such holder is entitled pursuant to Section 2.2(e) and (ii) at the
appropriate payment date, the amount of dividends or other distributions with a
record date after the Effective Time and with a payment date subsequent to such
surrender payable with respect to such whole shares of HealthWatch Common Stock.

  (d) NO FURTHER OWNERSHIP RIGHTS IN HALIS COMMON STOCK. All shares of
HealthWatch Common Stock issued upon the surrender for exchange of Certificates
in accordance with the terms of this Article II (including any cash paid
pursuant to this Article II) shall be deemed to have been issued (and paid) in
full satisfaction of all rights pertaining to the shares of Halis Common Stock
theretofore represented by such Certificates, and there shall be no further
registration of transfers on the stock transfer books of the Surviving
Corporation or HealthWatch of the shares of Halis Common Stock which were
outstanding immediately prior to the Effective Time. If, after the Effective
Time, Certificates are presented to HealthWatch, the Surviving Corporation or
the Exchange Agent for any reason, they shall be canceled and exchanged as
provided in this Article II, except as otherwise provided by law.

  (e) NO FRACTIONAL SHARES. Notwithstanding anything to the contrary contained
herein, no certificates or scrip representing fractional shares of HealthWatch
Common Stock shall be issued upon the surrender for exchange of Certificates, no
dividend or distribution of HealthWatch shall relate to such fractional share
interests and such fractional share interests will not entitle the owner thereof
to vote or to any rights of a stockholder of HealthWatch. In lieu of the
issuance of such fractional shares, HealthWatch shall pay each former holder of
Halis Common Stock an amount in cash equal to the product obtained by
multiplying (A) the fractional share interest to which such former holder would
otherwise be entitled by (B) the average closing price per share (or if there is
no sale on such date then the average between the closing bid and ask prices on
any such day) for shares of HealthWatch Common Stock as reported by the Nasdaq
SmallCap Market (as reported in The Wall Street Journal, or, if not reported
therein, any other authoritative source) during the ten trading days preceding
the Closing Date (such average, the "Average HealthWatch Price").

     (f) TERMINATION OF EXCHANGE FUND. Any portion of the Exchange Fund which
remains undistributed to the holders of the Certificates for six (6) months
after the Effective Time shall be delivered to HealthWatch, upon demand, and any
holders of the Certificates who have not theretofore complied with this Article
II shall thereafter look only to HealthWatch for payment of their claim for
Merger Consideration, any dividends or distributions with respect to HealthWatch
Common Stock and any cash in lieu of fractional shares of HealthWatch Common
Stock.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                          Page 6

     (g) NO LIABILITY. None of Halis, HealthWatch, Merger Sub or the Exchange
Agent shall be liable to any person in respect of any shares of HealthWatch
Common Stock, any dividends or distributions with respect thereto, any cash in
lieu of fractional shares of HealthWatch Common Stock or any cash from the
Exchange Fund, in each case delivered to a public official pursuant to any
applicable abandoned property, escheat or similar law.

     (h) INVESTMENT OF EXCHANGE FUND. The Exchange Agent shall invest any cash
included in the Exchange Fund, as directed by HealthWatch, on a daily basis. Any
interest and other income resulting from such investments shall be paid to
HealthWatch.

     (i) LOST CERTIFICATES. If any Certificate shall have been lost, stolen or
destroyed, upon the making of an affidavit of that fact by the person claiming
such Certificate to be lost, stolen or destroyed and, if required by the
Surviving Corporation, the posting by such person of a bond in such reasonable
amount as the Surviving Corporation may direct as indemnity against any claim
that may be made against it with respect to such Certificate, the Exchange Agent
shall issue in exchange for such lost, stolen or destroyed Certificate the
Merger Consideration and, if applicable, any unpaid dividends and distributions
on shares of HealthWatch Common Stock deliverable in respect thereof and any
cash in lieu of fractional shares, in each case pursuant to this Agreement.

     (j) HALIS DISSENTING SHARES.  Notwithstanding any provision of this
Agreement to the contrary, shares of Halis which are issued and outstanding
immediately prior to the Effective Time and which are held by Halis Shareholders
who have timely filed with Halis a written objection to the Merger (the
"Dissenting Shares") shall not be converted into or represent a right to receive
HealthWatch Common Stock, pursuant to Section 2.1 hereof, but the holder thereof
shall be entitled only to such rights as are granted by Article 13 of the
Georgia Business Corporation Code (O.C.G.A. (S) 14-2-1301 et seq.).  Each holder
of Dissenting Shares who becomes entitled to payment for such shares pursuant to
the foregoing statutory provision shall receive payment for their shares from
Halis in accordance with such statutory provision.  If such holder shall have
failed to perfect, or shall have effectively withdrawn or lost, his right to
appraisal and payment for his shares under such statutory provisions, each such
share shall be converted into and represent the right to receive shares of
HealthWatch Common Stock, pursuant to Section 2.1 hereof, upon surrender of the
certificate representing such share to Halis.

     SECTION 2.3 CERTAIN ADJUSTMENTS. If between the date hereof and the
Effective Time, the outstanding shares of HealthWatch Common Stock or of Halis
Common Stock shall be changed into a different number of shares by reason of any
reclassification, recapitalization, split-up, combination or exchange of shares,
or any dividend payable in stock or other securities shall be declared thereon
with a record date within such period, the Exchange Ratio shall be adjusted
accordingly to provide to the holders of Halis Common Stock the same economic
effect as contemplated by this Agreement prior to such reclassification,
recapitalization, split-up, combination, exchange or dividend.

                                  ARTICLE III
                        REPRESENTATIONS AND WARRANTIES

     SECTION 3.1 REPRESENTATIONS AND WARRANTIES OF HEALTHWATCH AND MERGER SUB.
Except as disclosed in the Disclosure Schedule delivered by HealthWatch and
Merger Sub to
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                          Page 7

Halis as contemplated by this Agreement (the "HealthWatch Disclosure Schedule")
and making reference to the particular subsection of this Agreement to which
exception is being taken, HealthWatch and Merger Sub jointly and severally
represent and warrant to Halis as follows:

     (a) ORGANIZATION, STANDING AND CORPORATE POWER.

          (i)  Each of HealthWatch and its subsidiaries (including Merger Sub)
(as defined in Section 8.3), is a corporation or other legal entity duly
organized, validly existing and in good standing (with respect to jurisdictions
which recognize such concept) under the laws of the jurisdiction in which it is
organized and has the requisite corporate or other power, as the case may be,
and authority to carry on its business as now being conducted, except for those
jurisdictions where the failure to be so organized, existing or in good standing
individually or in the aggregate would not have a material adverse effect (as
defined in Section 8.3) on HealthWatch.  Each of HealthWatch and its
subsidiaries is duly qualified or licensed to do business and is in good
standing (with respect to jurisdictions which recognize such concept) in each
jurisdiction in which the nature of its business or the ownership, leasing or
operation of its properties makes such qualification or licensing necessary,
except for those jurisdictions where the failure to be so qualified or licensed
or to be in good standing individually or in the aggregate would not have a
material adverse effect on HealthWatch.

          (ii) HealthWatch has delivered to Halis prior to the execution of this
Agreement complete and correct copies of any amendments to its articles of
incorporation (the "HealthWatch Articles") and by-laws not filed as of the date
hereof with the HealthWatch Filed SEC Documents (as defined in Section 3.1(e)).

          (iii) In all material respects, the minute books of HealthWatch and
its subsidiaries contain accurate records of all meetings and accurately reflect
all other actions taken by the stockholders, the Board of Directors and all
committees of the Board of Directors of HealthWatch (or, as the case may be,
each of its subsidiaries) through December 31, 1999.

     (b) SUBSIDIARIES. Exhibit 21 to HealthWatch's Annual Report on Form 10-KSB
for the fiscal year ended June 30, 1999 includes all the subsidiaries of
HealthWatch which as of the date of this Agreement are Significant Subsidiaries
(as defined in Rule 1-02 of Regulation S-X of the SEC). All the outstanding
shares of capital stock of, or other equity interests in, each such Significant
Subsidiary have been validly issued and are fully paid and nonassessable and are
owned directly or indirectly by HealthWatch, free and clear of all pledges,
claims, liens, charges, encumbrances and security interests of any kind or
nature whatsoever (collectively, "Liens") and free of any other restriction
(including any restriction on the right to vote, sell or otherwise dispose of
such capital stock or other ownership interests).

     (c) CAPITAL STRUCTURE. The authorized capital stock of HealthWatch consists
of 10,000,000 shares of HealthWatch Common Stock, par value $.05 per share
("HealthWatch Common Stock") and 1,000,000 shares of HealthWatch Preferred
Stock.  At the close of business on March 31, 2000 (as adjusted to reflect the
issuance of 20,050 shares of HealthWatch's Series D 8% Convertible Preferred
Stock on May 8, 2000), (i) 2,095,418 shares of HealthWatch Common Stock were
issued and outstanding; (ii) 5,000 shares of HealthWatch 6% Series A Preferred
Stock, 4,000 shares of HealthWatch Series C 8% Convertible Preferred Stock,
74,130 shares of HealthWatch Series D 8% Convertible Preferred Stock, and 66,886
shares of HealthWatch Series P Preferred Stock were issued and outstanding
(collectively "HealthWatch Preferred Stock"); (iii) 3,009,717 shares of
HealthWatch Common Stock were reserved for issuance pursuant to
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                          Page 8

HealthWatch Preferred Stock; (iv) 2,530,006 shares were reserved for issuance
pursuant to warrant conversion rights; and (v) 529,500 shares were reserved for
issuance pursuant to agent option conversion rights, as described in Section
3.1(c) of the HealthWatch Disclosure Schedule. All stock options, restricted
stock or other stock-based compensation, benefits or savings plans, agreements
or arrangements in which current or former employees or directors of HealthWatch
or its subsidiaries participate as of the date hereof (including, without
limitation, the plans set forth on Exhibit A attached hereto), complete and
correct copies of which, in each case as amended as of the date hereof, have
been filed as exhibits to the HealthWatch Filed SEC Documents or delivered to
Halis (such plans, collectively, the "HealthWatch Stock Plans"); Section 3.1(c)
of the HealthWatch Disclosure Schedule sets forth a complete and correct list,
as of March 31, 2000, of the number of shares of HealthWatch Common Stock
subject to employee stock options or other rights to purchase or receive
HealthWatch Common Stock granted under the HealthWatch Stock Plans
(collectively, "HealthWatch Employee Stock Options"). All outstanding shares of
capital stock of HealthWatch, and all shares which may be issued pursuant to the
Stock Plans when issued, are duly authorized, validly issued, fully paid and
nonassessable and not subject to preemptive rights. Except as set forth in this
Section 3.1(c) and except for changes since March 31, 2000 resulting from the
issuance of shares of HealthWatch Common Stock pursuant to the HealthWatch
Employee Stock Options, or as expressly permitted by this Agreement, (x) there
are not issued, reserved for issuance or outstanding (A) any shares of capital
stock or other voting securities of HealthWatch, (B) any securities of
HealthWatch or any HealthWatch subsidiary convertible into or exchangeable or
exercisable for shares of capital stock or voting securities of HealthWatch, (C)
any warrants, calls, options or other rights to acquire from HealthWatch or any
HealthWatch subsidiary (including any subsidiary trust), or obligations of
HealthWatch or any HealthWatch subsidiary to issue, any capital stock, voting
securities or securities convertible into or exchangeable or exercisable for
capital stock or voting securities of HealthWatch, and (y) there are no
outstanding obligations of HealthWatch or any HealthWatch subsidiary to
repurchase, redeem or otherwise acquire any such securities or to issue, deliver
or sell, or cause to be issued, delivered or sold, any such securities. There
are no outstanding (A) securities of HealthWatch or any HealthWatch subsidiary
convertible into or exchangeable or exercisable for shares of capital stock or
other voting securities or ownership interests in any HealthWatch subsidiary,
(B) warrants, calls, options or other rights to acquire from HealthWatch or any
HealthWatch subsidiary, and any obligation of HealthWatch or any HealthWatch
subsidiary to issue, any capital stock, voting securities or other ownership
interests in, or any securities convertible into or exchangeable or exercisable
for any capital stock, voting securities or ownership interests in, any
HealthWatch subsidiary or (C) obligations of HealthWatch or any HealthWatch
subsidiary to repurchase, redeem or otherwise acquire any such outstanding
securities of HealthWatch subsidiaries or to issue, deliver or sell, or cause to
be issued, delivered or sold, any such securities. Neither HealthWatch nor any
HealthWatch subsidiary is a party to any agreement restricting the purchase or
transfer of, relating to the voting of, requiring registration of, or granting
any preemptive or, except as provided by the terms of outstanding warrants, and
the terms of HealthWatch Employee Stock Options, antidilutive rights with
respect to, any securities of the type referred to in the two preceding
sentences (except for the antidilutive rights provided for in the HealthWatch
Series C 8% Convertible Preferred Stock and the Series D 8% Convertible
Preferred Stock). Other than the HealthWatch subsidiaries, HealthWatch does not
directly or indirectly beneficially own any securities or other beneficial
ownership interests in any other entity (except Halis) except for non-
controlling investments made in the ordinary course of business.

     (d) AUTHORITY; NONCONTRAVENTION.  Each of HealthWatch and Merger has all
requisite corporate power and authority to enter into this Agreement, subject to
the HealthWatch Stockholder Approval (as defined in Section 3.1(l)), to
consummate the transactions contemplated hereby and thereby. The execution
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                          Page 9

and delivery of this Agreement by each of HealthWatch and Merger Sub, and the
consummation by HealthWatch and Merger Sub of the transactions contemplated
hereby and thereby have been duly authorized by all necessary corporate action
on the part of HealthWatch and Merger Sub, subject, in the case of the Merger
and the issuance of HealthWatch Common Stock in connection with the Merger and
the conversion of the Assumed Options, to the HealthWatch Stockholder Approval.
This Agreement has been, duly executed and delivered by HealthWatch and Merger
Sub and, assuming the due authorization, execution and delivery thereof by
Halis, constitutes (or will constitute, as the case may be) the legal, valid and
binding obligation of HealthWatch and Merger Sub, enforceable against
HealthWatch and Merger Sub in accordance with its terms. The execution and
delivery of this Agreement does not and the consummation of the transactions
contemplated hereby and thereby and compliance with the provisions of this
Agreement will not, conflict with, or result in any violation of, or default
(with or without notice or lapse of time, or both) under, or give rise to a
right of termination, cancellation or acceleration of any obligation or loss of
a benefit under, or result in the creation of any Lien upon any of the
properties or assets of HealthWatch or any of its subsidiaries or in any
restriction on the conduct of HealthWatch's business or operations under, (i)
the HealthWatch Articles or the by-laws of HealthWatch or the comparable
organizational documents of any of its subsidiaries, (ii) any loan or credit
agreement, note, bond, mortgage, indenture, trust document, lease or other
agreement, instrument, permit, concession, franchise, license or similar
authorization applicable to HealthWatch or any of its subsidiaries or their
respective properties or assets or (iii) subject to the governmental filings and
other matters referred to in the following sentence, any judgment, order,
decree, statute, law, ordinance, rule or regulation applicable to HealthWatch or
any of its subsidiaries or their respective properties or assets, other than, in
the case of clauses (ii) and (iii), any such conflicts, violations, defaults,
rights, losses, restrictions or Liens that individually or in the aggregate
would not (x) have a material adverse effect on HealthWatch or Halis or (y)
reasonably be expected to impair the ability of HealthWatch or Merger Sub to
perform its obligations under this Agreement. No consent, approval, order or
authorization of, action by or in respect of, or registration, declaration or
filing with, any federal, state, local or foreign government, any court,
administrative, regulatory or other governmental agency, commission or authority
or any nongovernmental self-regulatory agency, commission or authority (a
"Governmental Entity") is required by or with respect to HealthWatch or any of
its subsidiaries in connection with the execution and delivery of this Agreement
by HealthWatch, or the consummation by HealthWatch or Merger Sub of the
transactions contemplated hereby and thereby, except for (1) the filing with the
SEC of (A) a proxy statement relating to the HealthWatch Stockholders' Meeting
(as defined in Section 5.1(b)) (such proxy statement which is combined with the
proxy statement relating to the Halis Stockholders' Meeting (as defined in
Section 5.1(c)), in each case as amended or supplemented from time to time, the
"Joint Proxy Statement"), (B) the Form S-4 and (C) such reports under Sections
13(a), 13(d), 15(d) or 16(a) of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), as may be required in connection with this Agreement, and
the transactions contemplated hereby and thereby; (2) the filing of the
Certificate of Merger with the Secretary of State of the State of Georgia and
appropriate documents with the relevant authorities of other states in which
Halis is qualified to do business and such filings with Governmental Entities to
satisfy the applicable requirements of state securities or "blue sky" laws; (3)
such filings and approvals of Nasdaq to permit the shares of HealthWatch Common
Stock that are to be issued in the Merger to be approved for listing, subject to
notice of issuance, by Nasdaq; and (4) such consents, approvals, orders or
authorizations the failure of which to be made or obtained individually or in
the aggregate would not (x) have a material adverse effect on HealthWatch or (y)
reasonably be expected to impair the ability of HealthWatch or Merger Sub to
perform its obligations under this Agreement.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 10

     (e) SEC DOCUMENTS; UNDISCLOSED LIABILITIES. HealthWatch has filed all
required registration statements, prospectuses, reports, schedules, forms,
statements and other documents (including exhibits and all other information
incorporated therein) with the SEC since December 31, 1997 (the "HealthWatch SEC
Documents"); however, HealthWatch did not hold a Shareholder Meeting for the
fiscal year end of June 30, 1999 and HealthWatch's Form 10-KSB for the year
ended June 30, 1998 is currently under review by the SEC. In addition, the proxy
statement for HealthWatch's annual meeting which was tentatively scheduled for
June 23, 2000 is currently being reviewed by the SEC. As of their respective
dates, the HealthWatch SEC Documents complied in all material respects with the
requirements of the Securities Act of 1933, as amended (the "Securities Act"),
or the Exchange Act, as the case may be, and the rules and regulations of the
SEC promulgated thereunder applicable to such HealthWatch SEC Documents, and
none of the HealthWatch SEC Documents when filed contained any untrue statement
of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. The financial
statements of HealthWatch included in the HealthWatch SEC Documents comply as to
form, as of their respective dates of filing with the SEC, in all material
respects with applicable accounting requirements and the published rules and
regulations of the SEC with respect thereto, have been prepared in accordance
with GAAP (except, in the case of unaudited statements, as permitted by Form 10-
QSB of the SEC) applied on a consistent basis during the periods involved
(except as may be indicated in the notes thereto) and fairly present the
consolidated financial position of HealthWatch and its consolidated subsidiaries
as of the dates thereof and the consolidated results of their operations and
cash flows for the periods then ended (subject, in the case of unaudited
statements, to normal year-end audit adjustments which are not material). Except
(i) as reflected in such financial statements or in the notes thereto or (ii)
for liabilities incurred in connection with this Agreement, or the transactions
contemplated hereby or thereby, neither HealthWatch nor any of its subsidiaries
has any liabilities or obligations of any nature which, individually or in the
aggregate, would have a material adverse effect on HealthWatch.

     (f) INFORMATION SUPPLIED. None of the information supplied or to be
supplied by HealthWatch specifically for inclusion or incorporation by reference
in (i) the registration statement on Form S-4 to be filed with the SEC by
HealthWatch in connection with the issuance of HealthWatch Common Stock in the
Merger (the "Form S-4") will, at the time the Form S-4 becomes effective under
the Securities Act, contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the
statements therein not misleading or (ii) the Joint Proxy Statement included
therein will, at the date it is first mailed to HealthWatch's stockholders or at
the time of the HealthWatch Stockholders' Meeting, contain any untrue statement
of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading. The Form S-4 and the
Joint Proxy Statement included therein will comply as to form in all material
respects with the requirements of the Securities Act and the Exchange Act and
the rules and regulations thereunder, except that no representation or warranty
is made by HealthWatch with respect to statements made or incorporated by
reference therein based on information supplied by Halis specifically for
inclusion or incorporation by reference in the Form S-4 or the Joint Proxy
Statement.

     (g) ABSENCE OF CERTAIN CHANGES OR EVENTS. Except for liabilities incurred
in connection with this Agreement, or the transactions contemplated hereby and
thereby, and except as permitted by Section 4.1(a) (and the sale of HealthWatch
Series D 8% Convertible Preferred Stock pursuant to that certain private
placement memorandum dated March 8, 2000), since March 31, 2000, HealthWatch and
its subsidiaries have conducted their business only in the ordinary course
consistent with past practice or as disclosed in any
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 11

HealthWatch SEC Documents filed since such date and prior to the date hereof,
and there has not been except as required by outstanding preferred stock and the
Additional Consideration Agreements: (i) any material adverse change (as defined
in Section 8.3) in HealthWatch, (ii) any declaration, setting aside or payment
of any dividend or other distribution (whether in cash, stock or property) with
respect to any of HealthWatch's capital stock, (iii) any split, combination or
reclassification of any of HealthWatch's capital stock or any issuance or the
authorization of any issuance of any other securities in respect of, in lieu of,
or in substitution for shares of HealthWatch's capital stock, except for
issuances of HealthWatch Common Stock upon exercise or conversion of HealthWatch
Employee Stock Options, in each case awarded prior to the date hereof in
accordance with their present terms or issued pursuant to Section 4.1(a),
(iv)(A) any granting by HealthWatch or any of its subsidiaries to any current or
former director, officer or other key employee of HealthWatch or its
subsidiaries of any increase in compensation, bonus or other benefits, except
for normal increases as a result of promotions, normal increases of base pay or
target bonuses in the ordinary course of business or as was required under any
employment agreements in effect as of December 31, 1999 or in connection with
the employment of and entering into an employment agreement with David Engert,
(B) any granting by HealthWatch or any of its subsidiaries to any such current
or former director, officer or key employee of any increase in severance or
termination pay or (C) any entry by HealthWatch or any of its subsidiaries into,
or any amendment of, any employment, deferred compensation, consulting,
severance, termination or indemnification agreement with any such current or
former director or officer, or any material amendment of any of the foregoing
with any key employee, except in connection with the employment of David Engert,
(v) except insofar as may have been disclosed in HealthWatch SEC Documents filed
and publicly available prior to the date of this Agreement (as amended to the
date hereof, the "HealthWatch Filed SEC Documents") or required by a change in
GAAP, any change in accounting methods, principles or practices by HealthWatch
materially affecting its assets, liabilities or business, (vi) except in so far
as may have been disclosed in the HealthWatch Filed SEC Documents, any tax
election that individually or in the aggregate would have a material adverse
effect on HealthWatch or any of its tax attributes or any settlement or
compromise of any material income tax liability, or (vii) any action taken by
HealthWatch or any of the HealthWatch subsidiaries during the period from
January 1, 2000 through the date of this Agreement that, if taken during the
period from the date of this Agreement through the Effective Time, would
constitute a breach of Section 4.1(a) (excepting the agency agreement made with
Commonwealth Associates, L.P. which acted as placement agent in the sale of the
HealthWatch Series D 8% Convertible Preferred Stock and Series C 8% Convertible
Preferred Stock (and related warrants)).

     (h) COMPLIANCE WITH APPLICABLE LAWS; LITIGATION.

          (i) HealthWatch, its subsidiaries and employees hold all permits,
licenses, variances, exemptions, orders, registrations and approvals of all
Governmental Entities which are required for the operation of the businesses of
HealthWatch and its subsidiaries (the "HealthWatch Permits"), except where the
failure to have any such HealthWatch Permits individually or in the aggregate
would not have a material adverse effect on HealthWatch. Except as specifically
disclosed in the HealthWatch SEC Documents filed with the Commission prior to
the date hereof, HealthWatch and its subsidiaries are in compliance with the
terms of the HealthWatch Permits and all applicable laws, statutes, orders,
rules, regulations, policies or guidelines promulgated, or judgments, decisions
or orders entered by any Governmental Entity, relating to HealthWatch or its
business or properties, except where the failure to be in compliance with such
Applicable Laws individually or in the aggregate would not have a material
adverse effect on HealthWatch. As of the date of this Agreement, except as
disclosed in the HealthWatch Filed SEC Documents, no action, demand, requirement
or investigation by any Governmental Entity and no suit, action or proceeding by
any person, in each case with respect to
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 12

HealthWatch or any of its subsidiaries or any of their respective properties, is
pending or, to the knowledge (as defined in Section 8.3) of HealthWatch,
threatened, other than, in each case, those the outcome of which individually or
in the aggregate would not (A) have a material adverse effect on HealthWatch or
(B) reasonably be expected to impair the ability of HealthWatch or Merger Sub to
perform its obligations under this Agreement or prevent or materially delay the
consummation of any of the transactions contemplated hereby or thereby.

          (ii) Neither HealthWatch nor any HealthWatch subsidiary is subject to
any outstanding order, injunction or decree which has had or, insofar as can be
reasonably foreseen, individually or in the aggregate will have, a material
adverse effect on HealthWatch.

          (iii) Although not a Governmental Entity, Nasdaq has required
HealthWatch to hold an annual shareholders meeting no later than June 30, 2000
to maintain its SmallCap listing.

     (i) ABSENCE OF CHANGES IN BENEFIT PLANS. HealthWatch has delivered to Halis
or provided to Halis for review true and complete copies of vacation, severance,
disability, death benefit, hospitalization, medical or other plan, arrangement
or understanding providing benefits to any current or former officers, directors
or employees of HealthWatch or any of its wholly owned subsidiaries
(collectively, the "HealthWatch Benefit Plans"). Since December 31, 1999,
neither HealthWatch nor any HealthWatch subsidiary has amended any HealthWatch
Employee Stock Options or any HealthWatch Stock Plans to accelerate the vesting
of, or release restrictions on, awards thereunder, or to provide for such
acceleration in the event of a change in control.

     (j) BENEFIT PLANS.

          (i) With respect to the HealthWatch Benefit Plans, to the knowledge of
HealthWatch, no event has occurred and there exists no condition or set of
circumstances, in connection with which HealthWatch or any of its subsidiaries
would be subject to any liability that individually or in the aggregate would
have a material adverse effect on HealthWatch under the Employee Retirement
Income Security Act of 1974, as amended ("ERISA"), the Code or any other
applicable law.

          (ii) Each HealthWatch Benefit Plan has been administered in accordance
with its terms, except for any failures so to administer any HealthWatch Benefit
Plan that individually or in the aggregate would not have a material adverse
effect on HealthWatch. To the knowledge of HealthWatch, the HealthWatch Benefit
Plans have been operated, and are, in compliance with the applicable provisions
of ERISA, the Code and all other applicable laws, except for any failures to be
in such compliance that individually or in the aggregate would not have a
material adverse effect on HealthWatch.

          (iii) No HealthWatch Benefit Plan provides medical benefits (whether
or not insured), with respect to current or former employees after retirement or
other termination of service (other than coverage mandated by applicable law or
benefits, the full cost of which is borne by the current or former employee) the
amounts of which are not material.

          (iv) HealthWatch has no collective bargaining or other labor union
contract applicable to persons employed by HealthWatch or any of its
subsidiaries.  No collective bargaining agreement is being negotiated or
renegotiated by HealthWatch or any of its subsidiaries. As of the date of this
Agreement, there is
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 13

no labor dispute, strike or work stoppage against HealthWatch or any of its
subsidiaries pending or, to the knowledge of HealthWatch, threatened which may
interfere with the respective business activities of HealthWatch or any of its
subsidiaries, except where such dispute, strike or work stoppage individually or
in the aggregate would not have a material adverse effect on HealthWatch. As of
the date of this Agreement, to the knowledge of HealthWatch, none of
HealthWatch, any of its subsidiaries or any of their respective representatives
or employees has committed any material unfair labor practice in connection with
the operation of the respective businesses of HealthWatch or any of its
subsidiaries, and there is no material charge or complaint against HealthWatch
of any of its subsidiaries by the National Labor Relations Board or any
comparable governmental agency pending or threatened in writing.

          (v) No employee of HealthWatch will be entitled to any material
payment, additional benefits or any acceleration of the time of payment or
vesting of any benefits under any HealthWatch Benefit Plan as a result of the
transactions contemplated by this Agreement (either alone or in conjunction with
any other event such as a termination of employment), except that substantially
all HealthWatch Employee Stock Options will vest as of the date on which
HealthWatch Stockholder Approval is obtained.

          (vi) No material oral or written representation or commitment with
respect to any aspect of any HealthWatch Benefit Plan has been or will be made
to employees of HealthWatch or any HealthWatch subsidiaries by an authorized
HealthWatch employee prior to the Closing Date that is not materially in
accordance with the written or otherwise preexisting terms and provisions of
such HealthWatch Benefit Plans in effect immediately prior to the Closing Date.

          (vii) Except such as would not have a material adverse effect, there
are no material unresolved claims or disputes under the terms of, or in
connection with, any HealthWatch Benefit Plan (other than routine undisputed
claims for benefits), and no action, legal or otherwise, has been commenced with
respect to any material claim.

     (k) TAXES.

          (i) Each of HealthWatch and its subsidiaries has filed all material
tax returns and reports required to be filed by it (taking into account all
applicable extensions) and all such returns and reports are complete and correct
in all material respects, or requests for extensions to file such returns or
reports have been timely filed, granted and have not expired, except to the
extent that such failures to file, to be complete or correct or to have
extensions granted that remain in effect individually or in the aggregate would
not have a material adverse effect on HealthWatch. HealthWatch and each of its
subsidiaries has paid (or HealthWatch has paid or caused to be paid on its
behalf) all taxes (as defined herein) shown as due on such returns, and the most
recent financial statements contained in the HealthWatch Filed SEC Documents
reflect an adequate reserve in accordance with GAAP for all taxes payable by
HealthWatch and its subsidiaries for all taxable periods and portions thereof
accrued through the date of such financial statements.

          (ii) No deficiencies for any taxes have, to the knowledge of
HealthWatch, been proposed, asserted or assessed against HealthWatch or any of
its subsidiaries that are not adequately reserved for, except for deficiencies
that individually or in the aggregate would not have a material adverse effect
on HealthWatch. Except as provided in Section 3.1(k) of the HealthWatch
Disclosure Schedule, all of the federal income tax
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 14

returns of the affiliated group of which HealthWatch is the common parent have
closed by virtue of the applicable statute of limitations.

          (iii) Neither HealthWatch nor any of its subsidiaries has taken any
action or knows of any fact, agreement, plan or other circumstance that is
reasonably likely to prevent the Merger from qualifying as a reorganization
within the meaning of Section 368(a) of the Code.

          (iv) As used in this Agreement, "taxes" shall include all (x) federal,
state, local or foreign income, property, sales, excise and other taxes or
similar governmental charges, including any interest, penalties or additions
with respect thereto, (y) liability for the payment of any amounts of the type
described in (x) as a result of being a member of an affiliated, consolidated,
combined or unitary group, and (z) liability for the payment of any amounts
described in (x) or (y) as a result of being party to any tax sharing agreement
or as a result of any express or implied obligation to indemnify any other
person with respect to the payment of any amounts of the type described in
clause (x) or (y).

          (v) Neither HealthWatch nor any HealthWatch subsidiary has made any
parachute payments as such term is defined in Section 280G of the Code, neither
is obligated to make any parachute payments, and neither is a party to any
agreement that under certain circumstances could obligate it, or any successor
in interest, to make any parachute payments that will not be deductible under
Section 280G of the Code. Neither HealthWatch nor any HealthWatch subsidiary is
obligated to make reimbursement or gross-up payments to any person in respect to
excess parachute payments.

     (l) VOTING REQUIREMENTS. The affirmative vote at the HealthWatch
Stockholders Meeting (the "HealthWatch Stockholder Approval") of the holders of
a majority of all outstanding shares of HealthWatch Common Stock, Series D 8%
Preferred Stock and Series C 8% Preferred Stock present in person or by proxy
and entitled to vote at a duly convened and held meeting of HealthWatch
Stockholders is the only vote of the holders of any class or series of
HealthWatch's capital stock necessary to approve and adopt this Agreement and
the transactions contemplated hereby, including the Merger.

     (m) STATE TAKEOVER STATUTES. The Board of Directors of HealthWatch and
Merger Sub have approved the Merger, this Agreement and the transactions
contemplated hereby and thereby, and such approval is sufficient to render
inapplicable to the Merger, this Agreement, and the transactions contemplated
hereby and thereby the provisions of Code Section 14-2-1110 et seq. and 14-2-
1131 et seq. of Georgia law to the extent, if any, such sections are applicable
to the Merger, this Agreement and the transactions contemplated hereby and
thereby.  No other state takeover statute or regulation applies to or purports
to apply to the Merger, this Agreement, or the transactions contemplated hereby
and thereby.

     (n) BROKERS. No broker, investment banker, financial advisor or other
person is entitled to any broker's, finder's, financial advisor's or other
similar fee or commission in connection with the transactions contemplated by
this Agreement based upon arrangements made by or on behalf of HealthWatch
(excepting the agency agreement with Commonwealth Associates, L.P. made in
conjunction with the sale of the Series C 8% Preferred Stock and Series D 8%
Convertible Preferred Stock of HealthWatch, wherein Commonwealth shall receive a
fee equal to 5% of the Merger Consideration).

     (o) INTELLECTUAL PROPERTY.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 15

          (i) Neither HealthWatch nor its subsidiaries owns any trademark,
patents or copyrights; however, HealthWatch and its subsidiaries own or have a
valid right to use all trademarks, service marks, trade names, Internet domain
names, designs, slogans and general intangibles of like nature, together with
all applications, registrations and goodwill related to the Software (as defined
below); technology, trade secrets and other confidential information, know-how,
proprietary processes, formulae, algorithms, models, and methodologies
(collectively, "Trade Secrets") used in or necessary for the conduct of
HealthWatch's and each of its subsidiary's business as currently conducted,
except where the failure to possess such right would not have a material adverse
effect (all such intellectual property being referred to herein as the
"Intellectual Property"). For purposes of this Section 3.1(p), "Software" means
any and all (a) computer programs, including any and all software
implementations of algorithms, models and methodologies, whether in source code
or object code, (b) databases and compilations, including any and all data and
collections of data, whether machine readable or otherwise, (c) descriptions,
flowcharts and other work product used to design, plan, organize and develop any
of the foregoing, (d) the technology supporting any Internet site(s) operated by
or on behalf of HealthWatch or any of its subsidiaries and (e) all
documentation, including user manuals and training materials, relating to any of
the foregoing.

          (ii) The Intellectual Property owned by HealthWatch or any of its
subsidiaries is free and clear of all Liens.

          (iii) The Intellectual Property owned by HealthWatch or any of its
subsidiaries and, to HealthWatch's knowledge, any Intellectual Property used by
HealthWatch, is valid and subsisting, in full force and effect, and has not been
canceled, expired, or abandoned. There is no pending or, to HealthWatch's
knowledge, threatened opposition, interference or cancellation proceeding before
any court or registration authority in any jurisdiction against any
registrations in respect of the Intellectual Property owned by HealthWatch or
any of its subsidiaries, or, to HealthWatch's knowledge, against any
Intellectual Property licensed to HealthWatch or any of its subsidiaries.

          (iv) To the actual knowledge of HealthWatch or any of its
subsidiaries, the conduct of the business of HealthWatch and its subsidiaries as
currently conducted does not infringe upon (either directly or indirectly such
as through contributory infringement or inducement to infringe) any intellectual
property rights owned or controlled by any third party. There are no claims or
suits pending or, to the knowledge of HealthWatch, threatened, and neither
HealthWatch nor any of its subsidiaries has received any notice of a third-party
claim or suit, (a) alleging that its activities or the conduct of its business
infringes upon, violates or constitutes the unauthorized use of the intellectual
property rights of any third party or (b) challenging the ownership, use,
validity or enforceability of any Intellectual Property, which in any case would
have a material adverse effect.

          (v) There are no settlements, forebearances to sue, consents,
judgments, orders or similar obligations which in any material respect (a)
restrict the right of HealthWatch or its subsidiaries to use any Intellectual
Property, or (b) restrict the business of HealthWatch or its subsidiaries in
order to accommodate a third party's intellectual property rights or (c) except
for licenses with customers for HealthWatch's Software, there are no agreements
that permit third parties to use any Intellectual Property owned or controlled
by HealthWatch or any of its subsidiaries.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 16

          (vi) HealthWatch and each of its subsidiaries take reasonable measures
to protect the confidentiality of Trade Secrets, including (i) requiring its
employees and independent contractors having access thereto to execute written
nondisclosure agreements and (ii) requiring all licensees to maintain the
confidentiality of its Trade Secrets. To the actual knowledge of HealthWatch or
its subsidiaries, no Trade Secret has been knowingly disclosed or authorized to
be disclosed to any third party other than pursuant to a nondisclosure agreement
or other appropriate instrument that adequately protects HealthWatch and the
applicable subsidiary's proprietary interests in and to such Trade Secrets. To
the knowledge of HealthWatch, no party to any nondisclosure agreement or
nondisclosure obligation relating to its Trade Secrets is in breach or default
thereof.

          (vii) To the knowledge of HealthWatch, no third party is
misappropriating, infringing, diluting or violating any Intellectual Property
owned by HealthWatch or any of its subsidiaries.

          (viii) The consummation of the transaction contemplated hereby shall
not result in the loss or impairment of HealthWatch's or of any subsidiary's
right to own or use any of the Intellectual Property, and will not require the
consent of any governmental authority, except where such loss or impairment or
the failure to obtain consent would not result in a material adverse effect.

          (ix) Neither HealthWatch nor any of its subsidiaries has entered into
any software license agreement in which it (a) failed to limit its liability to
the amount of licensing fees paid pursuant to the agreement; or (b) warranted as
to the performance or functionality of the Software other than stating that the
Software would perform in accordance with its documentation and/or
specifications; except in any case in which the contrary would not have a
material adverse effect.

     (p) CERTAIN CONTRACTS. Except as set forth in the HealthWatch Filed SEC
Documents, neither HealthWatch nor any of its subsidiaries is a party to or
bound by (i) any "material contract" (as such term is defined in Item 601(b)(10)
of Regulation S-K of the SEC), (ii) any non-competition agreement or any other
agreement or obligation which purports to limit in any material respect the
manner in which, or the localities in which, all or any material portion of the
business of HealthWatch and its subsidiaries (including, for purposes of this
Section 3.1(p), Halis and its subsidiaries, assuming the Merger has taken
place), taken as a whole, is or would be conducted, (iii) any exclusive supply
or purchase contracts or any exclusive requirements contracts or (iv) any
contract or other agreement which would prohibit or materially delay the
consummation of the Merger or any of the transactions contemplated by this
Agreement (all contracts of the type described in clauses (i) and (ii) being
referred to herein as "HealthWatch Material Contracts"). HealthWatch has
delivered to Halis or provided to Halis for review, prior to the execution of
this Agreement, complete and correct copies of all HealthWatch Material
Contracts not filed as exhibits to the HealthWatch Filed SEC Documents.  Each
HealthWatch Material Contract is valid and binding on HealthWatch (or, to the
extent a HealthWatch subsidiary is a party, such subsidiary) and is in full
force and effect, and HealthWatch and each HealthWatch subsidiary have in all
material respects performed all obligations required to be performed by them to
date under each HealthWatch Material Contract, except where such noncompliance,
individually or in the aggregate, would not have a material adverse effect on
HealthWatch. Neither HealthWatch nor any HealthWatch subsidiary knows of, or has
received notice of, any violation or default under (nor, to the knowledge of
HealthWatch, does there exist any condition which with the passage of time or
the giving of notice or both would result in such a violation or default under)
any HealthWatch Material Contract.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 17

     (q) ENVIRONMENTAL LIABILITY. Except as set forth in the HealthWatch Filed
SEC Documents, there are no legal, administrative, arbitral or other
proceedings, claims, actions, causes of action, private environmental
investigations or remediation activities or governmental investigations of any
nature pending or threatened against HealthWatch or any of its subsidiaries
seeking to impose, or that could reasonably be expected to result in the
imposition of, on HealthWatch or any of its subsidiaries, any liability or
obligation arising under common law or under any local, state or federal
environmental statute, regulation or ordinance, including, without limitation,
the Comprehensive Environmental Response, Compensation and Liability Act of
1980, as amended ("CERCLA"), which liability or obligation could reasonably be
expected to have a material adverse effect on HealthWatch. To the knowledge of
HealthWatch, there is no reasonable basis for any such proceeding, claim, action
or governmental investigation that would impose any liability or obligation that
could reasonably be expected to have a material adverse effect on HealthWatch.

     (r) INSURANCE. HealthWatch and each of its subsidiaries have policies of
insurance and bonds of the type and in amounts customarily carried by persons
conducting businesses or owning assets similar to those of HealthWatch and its
subsidiaries.  There is no claim pending under any of such policies or bonds as
to which coverage has been questioned, denied or disputed by the underwriters of
such policies or bonds, except questioned, denied or disputed claims the failure
to provide coverage for which would not, individually or in the aggregate, have
a material adverse effect on HealthWatch. All premiums due and payable under all
such policies and bonds have been paid and HealthWatch and its subsidiaries are
otherwise in compliance in all material respects with the terms of such policies
and bonds. HealthWatch has no knowledge of any threatened termination of, or
material premium increase with respect to, any of such policies.

     (s) TRANSACTIONS WITH AFFILIATES. Except as disclosed in the HealthWatch
SEC Documents filed prior to the date of this Agreement or as disclosed in the
HealthWatch Disclosure Schedule, since December 31, 1999, there have been no
transactions, agreements, arrangements or understandings between HealthWatch and
its affiliates that would be required to be disclosed under the Item 404 of
Regulation S-K under the Securities Act.

     (t) FULL DISCLOSURE. None of the representations or warranties made by
HealthWatch herein or in any schedule hereto, including the HealthWatch
Disclosure Schedule, or any certificate furnished by HealthWatch pursuant to
this Agreement, contains or will contain at the Effective Time any untrue
statement of a material fact, or omits or will omit at the Effective Time, to
state any material fact necessary in order to make the statements contained
herein or therein, in the light of the circumstances under which made, not
misleading.

     SECTION 3.2 REPRESENTATIONS AND WARRANTIES OF HALIS. Except as disclosed in
the Disclosure Schedule delivered by Halis to HealthWatch as contemplated by
this Agreement (the "Halis Disclosure Schedule") and making reference to the
particular subsection of this Agreement to which exception is being taken, Halis
represents and warrants to HealthWatch as follows:

     (a) ORGANIZATION, STANDING AND CORPORATE POWER.

          (i) Each of Halis and its subsidiaries (as defined in Section 8.3) is
a corporation or other legal entity duly organized, validly existing and in good
standing (with respect to jurisdictions which recognize such concept) under the
laws of the jurisdiction in which it is organized and has the requisite
corporate or other power, as the case may be, and authority to carry on its
business as now being conducted, except, as to
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 18

subsidiaries, for those jurisdictions where the failure to be so organized,
existing or in good standing individually or in the aggregate would not have a
material adverse effect (as defined in Section 8.3) on Halis. Each of Halis and
its subsidiaries is duly qualified or licensed to do business and is in good
standing (with respect to jurisdictions which recognize such concept) in each
jurisdiction in which the nature of its business or the ownership, leasing or
operation of its properties makes such qualification or licensing necessary,
except for those jurisdictions where the failure to be so qualified or licensed
or to be in good standing individually or in the aggregate would not have a
material adverse effect on Halis.

          (ii) Halis has delivered to HealthWatch prior to the execution of this
Agreement complete and correct copies of any amendments to its articles of
incorporation (the "Halis Certificate") and by-laws not filed as of the date
hereof with the Halis SEC Documents (as defined in Section 3.2(e)).

          (iii) In all material respects, the minute books of Halis and its
subsidiaries contain accurate records of all meetings and accurately reflect all
other actions taken by the stockholders, the Board of Directors and all
committees of the Board of Directors of Halis (or, as the case may be, each of
its subsidiaries) through December 31, 1999.

     (b) SUBSIDIARIES. Exhibit 21.1 to Halis' Annual Report on Form 10-KSB for
the fiscal year ended December 31, 1999 includes all the subsidiaries of Halis
which as of the date of this Agreement are Significant Subsidiaries (as defined
in Rule 1.02 of Regulation S-X of the SEC). All the outstanding shares of
capital stock of, or other equity interests in, each such Significant Subsidiary
have been validly issued and are fully paid and nonassessable and are owned
directly or indirectly by Halis, free and clear of all Liens and free of any
other restriction (including any restriction on the right to vote, sell or
otherwise dispose of such capital stock or other ownership interests).

     (c) CAPITAL STRUCTURE. The authorized capital stock of Halis consists of
100,000,000 shares of $.01 par value common stock ("Halis Common Stock") and
5,000,000 shares of $.10 par value shares of preferred stock ("Halis Preferred
Stock"). At the close of business on March 31, 2000 (as adjusted for the
issuance of 5,000,000 shares of Halis Common Stock to HealthWatch on April 29,
2000 in accordance with the terms of the financing option contained in the
Letter of Intent dated March 8, 2000): (i) 62,317,222  shares of Halis Common
Stock were issued and outstanding (15,763,655 shares of Halis are owned by
HealthWatch and the remaining shares are owned by others); (ii) no shares of
Halis Common Stock were held by Halis in its treasury; (iii) no shares of Halis
Preferred Stock were issued and outstanding; (iv) 12,780,290 shares of Halis
Common Stock were reserved for issuance pursuant to all stock options and
2,394,918 shares were reserved for issuance pursuant to warrant conversion
rights, as described in Section 3.2(c) of the Halis Disclosure Schedule. All
stock option, restricted stock or other stock based compensation, benefits or
savings plans, agreements or arrangements in which current or former employees
or directors of Halis or its subsidiaries participate as of the date hereof
(including, without limitation, the plans set forth on Exhibit B attached
hereto), complete and correct copies of which, in each case as amended as of the
date hereof, have been filed as exhibits to the Halis Filed SEC Documents or
delivered to HealthWatch (such plans, collectively, the "Halis Stock Plans");
Section 3.2(c) of the Halis Disclosure Schedule sets forth a complete and
correct list, as of March 31, 2000, of the number of shares of Halis Common
Stock subject to employee stock options or other rights to purchase or receive
Halis Common Stock granted under the Halis Stock Plans (collectively, "Halis
Employee Stock Options"). All outstanding shares of capital stock of Halis are,
and all shares which may be issued pursuant to this Agreement or otherwise will
be, when issued, duly authorized, validly issued, fully paid and nonassessable
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 19

and not subject to preemptive rights. Except as set forth in this Section
3.2(c), and except for changes since March 31, 2000 resulting from the issuance
of shares of Halis Common Stock pursuant to the Halis Employee Stock Options or
as expressly permitted by this Agreement, (x) there are not issued, reserved for
issuance or outstanding (A) any shares of capital stock or other voting
securities of Halis, (B) any securities of Halis or any Halis subsidiary
convertible into or exchangeable or exercisable for shares of capital stock or
voting securities of Halis, (C) any warrants, calls, options or other rights to
acquire from Halis or any Halis subsidiary, and any obligation of Halis or any
Halis subsidiary to issue, any capital stock, voting securities or securities
convertible into or exchangeable or exercisable for capital stock or voting
securities of Halis, and (y) there are no outstanding obligations of Halis or
any Halis subsidiary to repurchase, redeem or otherwise acquire any such
securities or to issue, deliver or sell, or cause to be issued, delivered or
sold, any such securities. There are no outstanding (A) securities of Halis or
any Halis subsidiary convertible into or exchangeable or exercisable for shares
of capital stock or other voting securities or ownership interests in any Halis
subsidiary, (B) warrants, calls, options or other rights to acquire from Halis
or any Halis subsidiary, or obligations of Halis or any Halis subsidiary to
issue, any capital stock, voting securities or other ownership interests in, or
any securities convertible into or exchangeable or exercisable for any capital
stock, voting securities or ownership interests in, any Halis subsidiary or (C)
obligations of Halis or any Halis subsidiary to repurchase, redeem or otherwise
acquire any such outstanding securities of Halis subsidiaries or to issue,
deliver or sell, or cause to be issued, delivered or sold, any such securities.
Neither Halis nor any Halis subsidiary is a party to any agreement restricting
the purchase or transfer of, relating to the voting of, requiring registration
of, or granting any preemptive or, except as provided by the terms of the Halis
Employee Stock Options, antidilutive rights with respect to, any securities of
the type referred to in the two preceding sentences. Other than the Halis
subsidiaries, Halis does not directly or indirectly beneficially own any
securities or other beneficial ownership interests in any other entity except
for non-controlling investments made in the ordinary course of business in
entities which are not individually or in the aggregate material to Halis and
its subsidiaries as a whole.

     (d) AUTHORITY; NONCONTRAVENTION. Halis has all requisite corporate power
and authority to enter into this Agreement, to and, subject to the Halis
Stockholder Approval (as defined in Section 3.2(l)), to consummate the
transactions contemplated hereby and thereby. The execution and delivery of this
Agreement by Halis and the consummation by Halis of the transactions
contemplated hereby and thereby have been duly authorized by all necessary
corporate action on the part of Halis, subject, in the case of the Merger, to
the Halis Stockholder Approval.  This Agreement has been duly executed and
delivered by Halis and, assuming the due authorization, execution and delivery
thereof by HealthWatch, constitutes (or will constitute, as the case may be) the
legal, valid and binding obligation of Halis, enforceable against Halis in
accordance with their terms. The execution and delivery of this Agreement does
not, and the consummation of the transactions contemplated hereby and thereby
and compliance with the provisions of this Agreement will not, conflict with, or
result in any violation of, or default (with or without notice or lapse of time,
or both) under, or give rise to a right of termination, cancellation or
acceleration of any obligation or loss of a benefit under, or result in the
creation of any Lien upon any of the properties or assets of Halis or any of its
subsidiaries or any restriction on the conduct of Halis's business or operations
under, (i) the Halis Certificate or the by-laws of Halis or the comparable
organizational documents of any of its subsidiaries, (ii) any loan or credit
agreement, note, bond, mortgage, indenture, trust document, lease or other
agreement, instrument, permit, concession, franchise, license or similar
authorization applicable to Halis or any of its subsidiaries or their respective
properties or assets or (iii) subject to the governmental filings and other
matters referred to in the following sentence, any judgment, order, decree,
statute, law, ordinance, rule or regulation applicable to Halis or any of its
subsidiaries or their respective properties or assets, other than, in the case
of clauses (ii) and (iii), any such conflicts, violations, defaults, rights,
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 20

losses, restrictions or Liens that individually or in the aggregate would not
(x) have a material adverse effect on Halis or (y) reasonably be expected to
impair the ability of Halis to perform its obligations under this Agreement. No
consent, approval, order or authorization of, action by, or in respect of, or
registration, declaration or filing with, any Governmental Entity is required by
or with respect to Halis or any of its subsidiaries in connection with the
execution and delivery of this Agreement or  by Halis or the consummation by
Halis of the transactions contemplated hereby or thereby, except for (1) the
filing with the SEC of (A) the Joint Proxy Statement relating to the Halis
Stockholders' Meeting, and (B) such reports under Sections 13(a), 13(d), 15(d)
or 16(a) of the Exchange Act as may be required in connection with this
Agreement and the transactions contemplated hereby and thereby; (2) the filing
of the Certificate of Merger with the Secretary of State of the State of Georgia
and appropriate documents with the relevant authorities of other states in which
Halis is qualified to do business and such filings with Governmental Entities to
satisfy the applicable requirements of state securities or "blue sky" laws; and
(3) such consents, approvals, orders or authorizations the failure of which to
be made or obtained individually or in the aggregate would not (x) have a
material adverse effect on Halis or (y) reasonably be expected to impair the
ability of Halis to perform its obligations under this Agreement.

     (e) SEC DOCUMENTS; UNDISCLOSED LIABILITIES. Halis has filed all required
registration statements, prospectuses, reports, schedules, forms, statements and
other documents (including exhibits and all other information incorporated
therein) with the SEC since December 31, 1997 (the "Halis SEC Documents");
however, Halis did not hold a Shareholders Meeting for fiscal years ending
December 31, 1998 and December 31, 1999 and Halis is delinquent in filing its
Form 10-KSB for fiscal year ending December 31, 1999.  As of their respective
dates, the Halis SEC Documents complied in all material respects with the
requirements of the Securities Act or the Exchange Act, as the case may be, and
the rules and regulations of the SEC promulgated thereunder applicable to such
Halis SEC Documents, and none of the Halis SEC Documents when filed contained
any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not
misleading. The financial statements of Halis included in the Halis SEC
Documents comply as to form, as of their respective dates of filing with the
SEC, in all material respects with applicable accounting requirements and the
published rules and regulations of the SEC with respect thereto, have been
prepared in accordance with GAAP (except, in the case of unaudited statements,
as permitted by Form 10-QSB of the SEC) applied on a consistent basis during the
periods involved (except as may be indicated in the notes thereto) and fairly
present the consolidated financial position of Halis and its consolidated
subsidiaries as of the dates thereof and the consolidated results of their
operations and cash flows for the periods then ended (subject, in the case of
unaudited statements, to normal year-end audit adjustments which are not
material). Except (i) as reflected in such financial statements or in the notes
thereto or (ii) for liabilities incurred in connection with this Agreement, or
the transactions contemplated hereby or thereby, neither Halis nor any of its
subsidiaries has any liabilities or obligations of any nature which,
individually or in the aggregate, would have a material adverse effect on Halis.

     (f) INFORMATION SUPPLIED. None of the information supplied or to be
supplied by Halis specifically for inclusion or incorporation by reference in
(i) the Form S-4 will, at the time the Form S-4 becomes effective under the
Securities Act, contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the
statements therein not misleading or (ii) the Joint Proxy Statement included in
the Form S-4 will, at the date it is first mailed to Halis' stockholders or at
the time of the Halis Stockholders' Meeting, contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements therein, in light of the
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 21

circumstances under which they are made, not misleading. The Joint Proxy
Statement will comply as to form in all material respects with the requirements
of the Securities Act and the Exchange Act and the rules and regulations
thereunder, except that no representation or warranty is made by Halis with
respect to statements made or incorporated by reference therein based on
information supplied by HealthWatch specifically for inclusion or incorporation
by reference in the Joint Proxy Statement.

     (g) ABSENCE OF CERTAIN CHANGES OR EVENTS. Except for liabilities incurred
in connection with this Agreement or the transactions contemplated hereby or
thereby, Halis and its subsidiaries have conducted their business only in the
ordinary course consistent with past practice or as disclosed in any Halis SEC
Document filed since such date and prior to the date hereof, and there has not
been (i) any material adverse change (as defined in Section 8.3) in Halis, (ii)
any declaration, setting aside or payment of any dividend or other distribution
(whether in cash, stock or property) with respect to any of Halis' capital
stock, (iii) any split, combination or reclassification of any of Halis' capital
stock or any issuance or the authorization of any issuance of any other
securities in respect of, in lieu of or in substitution for shares of Halis'
capital stock, except for issuances of Halis Common Stock upon exercise or
conversion of Halis Employee Stock Options, in each case awarded prior to the
date hereof in accordance with their present terms, (iv) (A) any granting by
Halis or any of its subsidiaries to any current or former director, officer or
other key employee of Halis or its subsidiaries of any increase in compensation,
bonus or other benefits, except for normal increases as a result of promotions,
normal increases of base pay or target bonuses in the ordinary course of
business or as was required under any employment agreements in effect as of
December 31, 1999, (B) any granting by Halis or any of its subsidiaries to any
such current or former director, officer or key employee of any increase in
severance or termination pay, or (C) any entry by Halis or any of its
subsidiaries into, or any amendment of, any employment, deferred compensation,
consulting, severance, termination or indemnification agreement with any such
current or former director, officer, or any material amendment of any of the
foregoing with any key employee, (v) except insofar as may have been disclosed
in Halis SEC Documents filed and publicly available prior to the date of this
Agreement (as amended to the date hereof, the "Halis Filed SEC Documents") or
required by a change in GAAP, any change in accounting methods, principles or
practices by Halis materially affecting its assets, liabilities or business,
(vi) except insofar as may have been disclosed in the Halis Filed SEC Documents,
any tax election that individually or in the aggregate would have a material
adverse effect on Halis or any of its tax attributes or any settlement or
compromise of any material income tax liability or (vii) any action taken by
Halis or any of the Halis subsidiaries during the period from December 31, 1999
through the date of this Agreement that, if taken during the period from the
date of this Agreement through the Effective Time, would constitute a breach of
Section 4.1(b).

     (h) COMPLIANCE WITH APPLICABLE LAWS; LITIGATION.

          (i) Halis, its subsidiaries and employees hold all permits, licenses,
variances, exemptions, orders, registrations and approvals of all Governmental
Entities which are required for the operation of the businesses of Halis and its
subsidiaries (the "Halis Permits") except where the failure to have any such
Halis Permits individually or in the aggregate would not have a material adverse
effect on Halis. Except as specifically disclosed in the Halis SEC Documents
filed with the Commission prior to the date hereof, Halis and its subsidiaries
are in compliance with the terms of the Halis Permits and all Applicable Laws
relating to Halis or its business or properties, except where the failure to be
in compliance with such Applicable Laws individually or in the aggregate would
not have a material adverse effect on Halis. As of the date of this Agreement,
except as disclosed in the Halis Filed SEC Documents, no action, demand,
requirement or
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 22

investigation by any Governmental Entity and no suit, action or proceeding by
any person, in each case with respect to Halis or any of its subsidiaries or any
of their respective properties, is pending or, to the knowledge of Halis,
threatened, other than, in each case, those the outcome of which individually or
in the aggregate would not (A) have a material adverse effect on Halis or (B)
reasonably be expected to impair the ability of Halis to perform its obligations
under this Agreement or prevent or materially delay the consummation of any of
the transactions contemplated hereby or thereby.

          (ii) Neither Halis nor any Halis subsidiary is subject to any
outstanding order, injunction or decree which has had or, insofar as can be
reasonably foreseen, individually or in the aggregate will have, a material
adverse effect on Halis.

     (i) ABSENCE OF CHANGES IN BENEFIT PLANS. Halis has delivered to HealthWatch
or provided to HealthWatch for review true and complete copies of any material
bonus, pension, profit sharing, deferred compensation, incentive compensation,
stock ownership, stock purchase, stock option, phantom stock, retirement,
vacation, severance, disability, death benefit, hospitalization, medical or
other plan, arrangement or understanding providing benefits to any current or
former officers, directors or employees of Halis or any of its wholly owned
subsidiaries (collectively, the "Halis Benefit Plans"), or any material change
in any actuarial or other assumption used to calculate funding obligations with
respect to any Halis pension plans, or any material change in the manner in
which contributions to any Halis pension plans are made or the basis on which
such contributions are determined. Since December 31, 1999, neither Halis nor
any Halis subsidiary has amended any Halis Employee Stock Options or any Halis
Stock Plans to accelerate the vesting of, or release restrictions on, awards
thereunder, or to provide for such acceleration in the event of a change in
control.

     (j) BENEFIT PLANS.

          (i) With respect to the Halis Benefit Plans, to the knowledge of
Halis, no event has occurred and there exists no condition or set of
circumstances, in connection with which Halis or any of its subsidiaries would
be subject to any liability that individually or in the aggregate could have a
material adverse effect on Halis under ERISA, the Code or any other applicable
law.

          (ii) Each Halis Benefit Plan has been administered in accordance with
its terms, except for any failures so to administer any Halis Benefit Plan that
individually or in the aggregate would not have a material adverse effect on
Halis. To the knowledge of Halis, the Halis Benefit Plans have been operated,
and are, in compliance with the applicable provisions of ERISA, the Code and all
other applicable laws, except for any failures to be in such compliance that
individually or in the aggregate would not have a material adverse effect on
Halis. Each Halis Benefit Plan that is intended to be qualified under Section
401(a) or 401(k) of the Code has received a favorable determination letter from
the IRS that  it is so qualified and each trust established in connection with
any Halis Benefit Plan that is intended to be exempt from federal income
taxation under Section 501(a) of the Code has received a determination letter
from the IRS that such trust is so exempt. To the knowledge of Halis, no fact or
event has occurred since the date of any determination letter from the IRS which
is reasonably likely to affect adversely the qualified status of any such Halis
Benefit Plan or the exempt status of any such trust.

          (iii) No Halis Benefit Plan is subject to Title IV of ERISA or is a
"multi-employer plan" within the meaning of Section 3(37) of ERISA.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 23

          (iv) No Halis Benefit Plan provides medical benefits (whether or not
insured),with respect to current or former employees after retirement or other
termination of service (other than coverage mandated by applicable law or
benefits, the full cost of which is borne by the current or former employee)
other than individual arrangements the amounts of which are not material.

          (v) No employee of Halis will be entitled to any material payment,
additional benefits or any acceleration of the time of payment or vesting of any
benefits under any Halis Benefit Plan as a result of the transactions
contemplated by this Agreement (either alone or in conjunction with any other
event such as a termination of employment).

          (vi) No material oral or written representation or commitment with
respect to any aspect of any Halis Benefit Plan has been or will be made to
employees of Halis or any Halis subsidiaries by an authorized Halis employee
prior to the Closing Date that is not materially in accordance with the written
or otherwise preexisting terms and provisions of such Halis Benefit Plans in
effect immediately prior to the Closing Date.

          (vii) Except as would not have a material adverse effect, there are no
material unresolved claims or disputes under the terms of, or in connection
with, any Halis Benefit Plan (other than routine undisputed claims for
benefits), and no action, legal or otherwise, has been commenced with respect to
any material claim.

          (viii) To the knowledge of Halis, no non-exempt "prohibited
transaction" (within the meaning of Section 4975(c) of the Tax Code) involving
any Halis Benefit Plan has occurred that could subject Halis to any material tax
penalty or other cost or liability (by indemnification or otherwise).

     (k) TAXES.

          (i) Each of Halis and its subsidiaries has filed all material tax
returns and reports required to be filed by it (taking into account applicable
extensions) and all such returns and reports are complete and correct in all
material respects, or requests for extensions to file such returns or reports
have been timely filed, granted and have not expired, except to the extent that
such failures to file, to be complete or correct or to have extensions granted
that remain in effect individually or in the aggregate would not have a material
adverse effect on Halis (except Halis has not yet filed its 1998 and 1999
Federal Income Tax Return). Halis and each of its subsidiaries has paid (or
Halis has paid or caused to be paid on its behalf) all taxes shown as due on
such returns, if any,  and the most recent financial statements contained in the
Halis Filed SEC Documents reflect an adequate reserve in accordance with GAAP
for all taxes payable by Halis and its subsidiaries, if any, for all taxable
periods and portions thereof accrued through the date of such financial
statements.

          (ii) No deficiencies for any taxes have, to the knowledge of Halis,
been proposed, asserted or assessed against Halis or any of its subsidiaries
that are not adequately reserved for, except for deficiencies that individually
or in the aggregate would not have a material adverse effect on Halis. Except as
provided in Section 3.2(k) of the Halis Disclosure Schedule, all of the federal
income tax returns of the affiliated group of which Halis is the common parent
have closed by virtue of the applicable statute of limitations.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 24

          (iii) Neither Halis nor any of its subsidiaries has taken any action
or knows of any fact, agreement, plan or other circumstance that is reasonably
likely to prevent the Merger from qualifying as a reorganization within the
meaning of Section 368(a) of the Code.

          (iv) Neither Halis nor any Halis subsidiary has made any parachute
payments as such term is defined in Section 280G of the Tax Code, neither is
obligated to make any parachute payments, and neither is a party to any
agreement that under certain circumstances could obligate it, or any successor
in interest, to make any parachute payments that will not be deductible under
Section 280G of the Tax Code. Neither Halis nor any Halis subsidiary is
obligated to make reimbursement or gross-up payments to any person in respect to
excess parachute payments.

     (l) VOTING REQUIREMENTS. The affirmative vote at the Halis Stockholders'
Meeting (the "Halis Stockholder Approval") of the holders of a majority of all
outstanding shares of Halis Common Stock entitled to vote at a duly convened and
held meeting of Halis stockholders is the only vote of the holders of any class
or series of Halis' capital stock necessary to approve and adopt this Agreement
and the transactions contemplated hereby, including the Merger. Prior to the
Halis Stockholders' Meeting, Halis Stockholders shall be provided the requisite
notice that they are entitled to assert dissenters' rights under Georgia
Business Corporate Code Section 14-2-1302 and a copy of Article 13 of the
Georgia Business Corporation Code dealing with dissenters' rights shall
accompany the notice.

     (m) STATE TAKEOVER STATUTES. The Board of Directors of Halis has approved
the Merger, this Agreement and the transactions contemplated hereby and
thereby, and such approval is sufficient to render inapplicable to the Merger,
this Agreement, and the transactions contemplated hereby and thereby the
provisions of Code Section 14-2-1110 et seq. and 14-2-1131 et seq. of Georgia
law to the extent, if any, such sections are applicable to the Merger, this
Agreement and the transactions contemplated hereby and thereby.  No other state
takeover statute or regulation applies to or purports to apply to the Merger,
this Agreement, or the transactions contemplated hereby and thereby.

     (n) BROKERS. No broker, investment banker, financial advisor or other
person is entitled to any broker's, finder's, financial advisor's or other
similar fee or commission in connection with the transactions contemplated by
this Agreement based upon arrangements made by or on behalf of Halis.

     (o) INTELLECTUAL PROPERTY.

          (i) Halis or its subsidiaries own or have a valid right to use all
trademarks, service marks, trade names, Internet domain names, designs, slogans,
and general intangibles of like nature, together with all applications,
registrations and goodwill related to the foregoing (collectively,
"Trademarks"); Software (as defined below); technology, trade secrets and other
confidential information, know-how, proprietary processes, formulae, algorithms,
models, and methodologies (collectively, "Trade Secrets") used in or necessary
for the conduct of Halis' and each of its subsidiary's business as currently
conducted, except where the failure to possess such right would not have a
material adverse effect (all such intellectual property being referred to herein
as the "Intellectual Property"). For purposes of this Section 3.2(o), "Software"
means any and all (a) computer programs, including any and all software
implementations of algorithms, models and methodologies, whether in source code
or object code, (b) databases and compilations, including any and all data and
collections of data, whether machine readable or otherwise, (c) descriptions,
flowcharts and other work product
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 25

used to design, plan, organize and develop any of the foregoing, (d) the
technology supporting any Internet site(s) operated by or on behalf of Halis or
any of its subsidiaries and (e) all documentation, including user manuals and
training materials, relating to any of the foregoing.

          (ii) The Intellectual Property owned by Halis or any subsidiary is
free and clear of all Liens.

          (iii) The Intellectual Property owned by Halis or any of its
subsidiaries and, to Halis' knowledge, any Intellectual Property used by Halis,
is valid and subsisting, in full force and effect, and has not been canceled,
expired, or abandoned.  There is no pending or, to Halis' knowledge, threatened
opposition, interference or cancellation proceeding before any court or
registration authority in any jurisdiction against any registrations in respect
of the Intellectual Property owned by Halis or any of its subsidiaries, or, to
Halis' knowledge, against any Intellectual Property licensed to Halis or any of
its subsidiaries.

          (iv) To the actual knowledge of Halis or any of its subsidiaries, the
conduct of the business of Halis and its subsidiaries as currently conducted
does not infringe upon (either directly or indirectly such as through
contributory infringement or inducement to infringe) any intellectual property
rights owned or controlled by any third party. There are no claims or suits
pending or, to the knowledge of Halis, threatened, and neither Halis nor any of
its subsidiaries has received any notice of a third-party claim or suit, (a)
alleging that its activities or the conduct of its business infringes upon,
violates, or constitutes the unauthorized use of the intellectual property
rights of any third party or (b) challenging the ownership, use, validity or
enforceability of any Intellectual Property, which in any case would have a
material adverse effect.

          (v) There are no settlements, forebearances to sue, consents,
judgments, orders or similar obligations which in any material respect (a)
restrict the right of Halis or its subsidiaries to use any Intellectual
Property, (b) restrict the business of Halis or its subsidiaries in order to
accommodate a third party's intellectual property rights or (c) except for
licenses with customers for Halis' Software, there are no agreements that permit
third parties to use any Intellectual Property owned or controlled by Halis or
any of its subsidiaries.

          (vi) Halis and each of its subsidiaries take reasonable measures to
protect the confidentiality of Trade Secrets, including (i) requiring its
employees and independent contractors having access thereto to execute written
nondisclosure agreements and (ii) requiring all licensees to maintain the
confidentiality of its Trade Secrets. To the actual knowledge of Halis or its
subsidiaries, no Trade Secret has been knowingly disclosed or authorized to be
disclosed to any third party other than pursuant to a nondisclosure agreement or
other appropriate instrument that adequately protects Halis and the applicable
subsidiary's proprietary interests in and to such Trade Secrets. To the
knowledge of Halis, no party to any nondisclosure agreement or nondisclosure
obligation relating to its Trade Secrets is in breach or default thereof.

          (vii) To the knowledge of Halis, no third party is misappropriating,
infringing, diluting or violating any Intellectual Property owned by Halis or
any of its subsidiaries other than immaterial disputes concerning use by a third
party of Trademarks of Halis or a subsidiary.

          (viii) The consummation of the transaction contemplated hereby shall
not result in the loss or impairment of Halis' or of any subsidiary's right to
own or use any of the Intellectual Property, and will not require the consent of
any governmental authority, except where such loss or impairment or the failure
to obtain consent would not result in a material adverse effect.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 26

          (ix) Neither Halis nor any of its subsidiaries has entered into any
software license agreement in which it (a) failed to limit its liability to the
amount of licensing fees paid pursuant to the agreement; or (b) warranted as to
the performance or functionality of the Software other than stating that the
Software would perform in accordance with its documentation and/or
specifications; except in any case in which the contrary would not have a
material adverse effect.

     (p) CERTAIN CONTRACTS. Except as set forth in the Halis Filed SEC Documents
or listed in Section 3.2(p) of the Halis Disclosure Schedule, neither Halis nor
any of its subsidiaries is a party to or bound by (i) any "material contract"
(as such term is defined in Item 601(b)(10) of Regulation S-K of the SEC), (ii)
any non-competition agreement or any other agreement or obligation which
purports to limit in any material respect the manner in which, or the localities
in which, all or any material portion of the business of Halis and its
subsidiaries (including, for purposes of this Section 3.2(p), HealthWatch and
its subsidiaries, assuming the Merger has taken place), taken as a whole, is or
would be conducted, (iii) any exclusive supply or purchase contracts or any
exclusive requirements contracts or (iv) any contract or other agreement which
would prohibit or materially delay the consummation of the Merger or any of the
transactions contemplated by this Agreement (all contracts of the type described
in clauses (i) and (ii) being referred to herein as "Halis Material Contracts").
Halis has delivered to HealthWatch or made available to HealthWatch for review,
prior to the execution of this Agreement, complete and correct copies of all
Halis Material Contracts not filed as exhibits to the Halis Filed SEC Documents.
Each Halis Material Contract is valid and binding on Halis (or, to the extent a
Halis subsidiary is a party, such subsidiary) and is in full force and effect,
and Halis and each Halis subsidiary have in all material respects performed all
obligations required to be performed by them to date under each Halis Material
Contract, except where such noncompliance, individually or in the aggregate,
would not have a material adverse effect on Halis. Neither Halis nor any Halis
subsidiary knows of, or has received notice of, any violation or default under
(nor, to the knowledge of Halis, does there exist any condition which with the
passage of time or the giving of notice or both would result in such a violation
or default under) any Halis Material Contract.

     (q) ENVIRONMENTAL LIABILITY. Except as set forth in the Halis Filed SEC
Documents, there are no legal, administrative, arbitral or other proceedings,
claims, actions, causes of action, private environmental investigations or
remediation activities or governmental investigations of any nature pending or
threatened against Halis or any of its subsidiaries seeking to impose, or that
could reasonably be expected to result in the imposition, on Halis or any of its
subsidiaries, of any liability or obligation arising under common law or under
any local, state or federal environmental statute, regulation or ordinance,
including, without limitation, CERCLA, which liability or obligation could
reasonably be expected to have a material adverse effect on Halis. To the
knowledge of Halis, there is no reasonable basis for any such proceeding, claim,
action or governmental investigation that would impose any liability or
obligation that could reasonably be expected to have a material adverse effect
on Halis.

     (r) INSURANCE. Halis and each of its subsidiaries have policies of
insurance and bonds of the type and in amounts customarily carried by persons
conducting businesses or owning assets similar to those of Halis and its
subsidiaries. There is no material claim pending under any of such policies or
bonds as to which coverage has been questioned, denied or disputed by the
underwriters of such policies or bonds, except questioned, denied or disputed
claims the failure to provide coverage for which would not, individually or in
the aggregate, have a material adverse effect on Halis. All premiums due and
payable under all such policies and bonds have been paid and Halis and its
subsidiaries are otherwise in compliance in all material respects with the
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 27

terms of such policies and bonds. Halis has no knowledge of any threatened
termination of, or material premium increase with respect to, any of such
policies.

     (s) TRANSACTIONS WITH AFFILIATES. Except as disclosed in the Halis SEC
Documents filed prior to the date of this Agreement or as disclosed in the Halis
Disclosure Schedule, since December 31, 1999, there have been no transactions,
agreements, arrangements or understandings between Halis and its affiliates that
would be required to be disclosed under the Item 404 of Regulation S-K under the
Securities Act.

     (t) FULL DISCLOSURE. None of the representations or warranties made by
Halis herein or in any schedule hereto, including the Halis Disclosure Schedule,
or any certificate furnished by Halis pursuant to this Agreement, contains or
will contain at the Effective Time any untrue statement of a material fact, or
omits or will omit at the Effective Time, to state any material fact necessary
in order to make the statements contained herein or therein, in the light of the
circumstances under which made, not misleading.

                                  ARTICLE IV
                   COVENANTS RELATING TO CONDUCT OF BUSINESS

     SECTION 4.1 CONDUCT OF BUSINESS.

     (a) CONDUCT OF BUSINESS BY HEALTHWATCH. Except as set forth in Section
4.1(a) of the HealthWatch Disclosure Schedule, as otherwise expressly
contemplated by this Agreement or as consented to by Halis in writing, such
consent not to be unreasonably withheld or delayed, during the period from the
date of this Agreement to the Effective Time, HealthWatch shall, and shall cause
its subsidiaries to, carry on their respective businesses in the ordinary course
consistent with past practice and in compliance in all material respects with
all applicable laws and regulations and, to the extent consistent therewith, use
all reasonable efforts to preserve intact their current business organizations,
use reasonable efforts to keep available the services of their current officers
and other key employees and preserve their relationships with those persons
having business dealings with them to the end that their goodwill and ongoing
businesses shall be unimpaired at the Effective Time.

     (b) CONDUCT OF BUSINESS BY HALIS.  Except as set forth in Section 4.1(b) of
the Halis Disclosure Schedule, as otherwise expressly contemplated by this
Agreement or as consented to by HealthWatch in writing, such consent not to be
unreasonably withheld or delayed, during the period from the date of this
Agreement to the Effective Time, Halis shall, and shall cause its subsidiaries
to, carry on their respective businesses in the ordinary course consistent with
past practice and in compliance in all material respects with all applicable
laws and regulations and, to the extent consistent therewith, use all reasonable
efforts to preserve intact their current business organizations, use reasonable
efforts to keep available the services of their current officers and other key
employees and preserve their relationships with those persons having business
dealings with them to the end that their goodwill and ongoing businesses shall
be unimpaired at the Effective Time.

     (c) OTHER ACTIONS. Except as required by law, HealthWatch and Halis shall
not, and shall not permit any of their respective subsidiaries to, voluntarily
take any action that would, or that could reasonably be expected to, result in
(i) any of the representations and warranties of such party set forth in this
Agreement that are qualified as to materiality becoming untrue at the Effective
Time, (ii) any of such representations and

<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 28

warranties that are not so qualified becoming untrue in any material respect at
the Effective Time, or (iii) any of the conditions to the Merger set forth in
Article VI not being satisfied.

     (d) ADVISE OF CHANGES. HealthWatch and Halis shall promptly advise the
other party orally and in writing to the extent it has knowledge of (i) any
representation or warranty made by it contained in this Agreement that is
qualified as to materiality becoming untrue or inaccurate in any respect or any
such representation or warranty that is not so qualified becoming untrue or
inaccurate in any material respect, (ii) the failure by it to comply in any
material respect with or satisfy in any material respect any covenant, condition
or agreement to be complied with or satisfied by it under this Agreement and
(iii) any change or event having, or which, insofar as can reasonably be
foreseen, could reasonably be expected to have a material adverse effect on such
party or on the truth of such party's representations and warranties or the
ability of the conditions set forth in Article VI to be satisfied; provided,
however, that no such notification shall affect their presentations, warranties,
covenants or agreements of the parties (or remedies with respect thereto) or the
conditions to the obligations of the parties under this Agreement.

     SECTION 4.2 NO SOLICITATION BY HALIS.

     (a) Halis shall not, nor shall it permit any of its subsidiaries to, nor
shall it authorize or permit any of its officers, directors or employees or any
investment banker, financial advisor, attorney, accountant or other
representative retained by it or any of its subsidiaries to, directly or
indirectly through another person, (i) solicit, initiate or encourage (including
by way of furnishing information), or take any other action designed to
facilitate, any inquiries or the making of any proposal the consummation of
which would constitute an Alternative Transaction (as hereinafter defined) or
(ii) participate in any discussions or negotiations regarding any Alternative
Transaction; provided, however, that if, at any time prior to the adoption of
this Agreement by the holders of Halis Common Stock, the Board of Directors of
Halis determines in good faith, after receipt of advice from outside counsel,
that the failure to provide such information or participate in such negotiations
or discussions would result in a reasonable possibility that the Board of
Directors of Halis breach its fiduciary duties to Halis' stockholders under
applicable law, Halis may, in response to any such proposal that was not
solicited by it or which did not otherwise result from a breach of this Section
4.2(a), and subject to compliance with Section 4.2(c), (x) furnish information
with respect to Halis and its subsidiaries to any person pursuant to a customary
confidentiality agreement containing terms as to confidentiality no less
restrictive than the Confidentiality Agreement and (y) participate in
negotiations regarding such proposal.

     (b) For purposes of this Agreement "Alternative Transaction" means any of
(i) a transaction or series of transactions pursuant to which any person (or
group of persons) other than Halis and its subsidiaries (a "Third Party")
acquires or would acquire, directly or indirectly, beneficial ownership (as
defined in Rule 13d-3 under the Exchange Act) of more than 20% of the
outstanding shares of Halis whether from Halis or pursuant to a tender offer or
exchange offer or otherwise, (ii) any acquisition or proposed acquisition of
Halis or any of its significant subsidiaries or by a merger or other business
combination (including any so called "merger of equals" and whether or not Halis
or any of its significant subsidiaries is the entity surviving any such merger
or business combination) or (iii) any other transaction pursuant to which any
Third Party acquires or would acquire, directly or indirectly, control of assets
(including for this purpose the outstanding equity securities of subsidiaries of
Halis and any entity surviving any merger or combination including any of them)
of Halis or any of its subsidiaries for consideration equal to 20% or more of
the fair market value of all of the outstanding
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 29

shares of Halis Common Stock or all of the outstanding shares of HealthWatch
Common Stock, as the case may be, on the date prior to the date hereof.

     (c) Neither the Board of Directors of Halis nor any committee thereof shall
(i) except as expressly permitted by this Section 4.2, withdraw, qualify or
modify, or propose publicly to withdraw, qualify or modify, in a manner adverse
to HealthWatch, the approval or recommendation by such Board of Directors or
such committee of the Merger, or this Agreement, (ii) approve or recommend, or
propose publicly to approve or recommend, any Alternative Transaction, or (iii)
cause Halis to enter into any letter of intent, agreement in principle,
acquisition agreement or other similar agreement (each, an "Halis Acquisition
Agreement") related to any Alternative Transaction. Notwithstanding the
foregoing, in the event that prior to the adoption of this Agreement by the
holders of Halis Common Stock the Board of Directors of Halis determines in good
faith, after it has received a Halis Superior Proposal (as defined below) and
after receipt of advice from outside counsel, that the failure to do so would
result in a reasonable possibility that the Board of Directors of Halis would
breach its fiduciary duties to Halis' stockholders under applicable law, the
Board of Directors of Halis may (subject to this and the following sentences)
inform Halis stockholders that it no longer believes that the Merger or this
Agreement is advisable and no longer recommends approval (a "Halis Subsequent
Determination"), but only at a time that is after the fifth business day
following HealthWatch's receipt of written notice advising HealthWatch that the
Board of Directors of Halis has received a Halis Superior Proposal, specifying
the material terms and conditions of such Halis Superior Proposal, identifying
the person making such Halis Superior Proposal and stating that it intends to
make a Halis Subsequent Determination. After providing such notice, Halis shall
provide a reasonable opportunity to HealthWatch to make such adjustments in the
terms and conditions of this Agreement and/or of the Halis Option Agreement as
would enable Halis to proceed with its recommendation to stockholders without
making a Halis Subsequent Determination; provided, however, that any such
adjustments shall be at the discretion of the parties at such time. For purposes
of this Agreement, a "Halis Superior Proposal" means any proposal (on its most
recently amended or modified terms, if amended or modified) made by a Third
Party to enter into an Alternative Transaction on terms which the Board of
Directors of Halis determines in its good faith judgment (based on the advice of
a financial advisor of nationally recognized reputation) to be more favorable to
Halis' stockholders than the Merger taking into account all relevant factors
(including whether, in the good faith judgment of the Board of Directors of
Halis, after obtaining advice from a financial advisor of nationally recognized
reputation, the third party is reasonably able to finance the transaction, and
any proposed changes to this Agreement and/or the Halis Option Agreement that
may be proposed by HealthWatch in response to such Alternative Transaction).
Notwithstanding any other provision of this Agreement, Halis shall submit this
Agreement to its stockholders whether or not the Board of Directors of Halis
make a Halis Subsequent Determination.

     (d) In addition to the obligations of Halis set forth in paragraphs (a) and
(b) of this Section 4.2, Halis shall promptly advise HealthWatch orally and in
writing of any request for information or of any proposal in connection with an
Alternative Transaction, the material terms and conditions of such request or
proposal and the identity of the person making such request or proposal. Halis
will keep HealthWatch reasonably informed of the status and details (including
amendments or proposed amendments) of any such request or proposal on a current
basis.

     (e) Nothing contained in this Section 4.2 shall prohibit Halis from (i)
taking and disclosing to its stockholders a position contemplated by Rule 14d-9
or Rule 14e-2(a) promulgated under the Exchange Act or (ii) from making any
disclosure to its stockholders if, in the good faith judgment of the Board of
Directors of
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 30

Halis, after receipt of advice from outside counsel, failure so to disclose
would be inconsistent with its fiduciary duties to Halis' stockholders under
applicable law.

     SECTION 4.3  HEALTHWATCH PRIVATE PLACEMENT.  Nothing contained in this
Agreement shall prohibit HealthWatch from issuing additional securities pursuant
to that certain Private Placement Memorandum dated March 8, 2000 relating to its
Series D Preferred Stock and warrants and such sale of additional securities
shall in no way be deemed a breach of the representation made by HealthWatch in
Section 3.1 hereof.

                                   ARTICLE V
                             ADDITIONAL AGREEMENTS

     SECTION 5.1 PREPARATION OF THE FORM S-4 AND THE JOINT PROXY STATEMENT;
STOCKHOLDERS' MEETINGS.

     (a) As soon as practicable following the date of this Agreement,
HealthWatch shall prepare the Form S-4 and HealthWatch and Halis shall prepare
the Joint Proxy Statement to be included in the Form S-4 and HealthWatch shall
cause such Form S-4 so prepared to be filed with the SEC.  Each of HealthWatch
and Halis shall use commercially reasonable efforts to have the Form S-4
declared effective under the Securities Act as promptly as practicable after
such filing. HealthWatch will use all commercially reasonable efforts to cause
the Joint Proxy Statement to be mailed to HealthWatch's stockholders, and Halis
will use all commercially reasonable efforts to cause the Joint Proxy Statement
to be mailed to Halis' stockholders, in each case as promptly as practicable
after the Form S-4 is declared effective under the Securities Act. HealthWatch
shall also take any action (other than qualifying to do business in any
jurisdiction in which it is not now so qualified or to file a general consent to
service of process) required to be taken under any applicable state securities
laws in connection with the issuance of HealthWatch Common Stock in the Merger
and the conversion of Assumed Options, and Halis shall furnish all information
concerning Halis and the holders of Halis Common Stock as may be reasonably
requested in connection with any such action. No filing of, or amendment or
supplement to, the Form S-4 or the Joint Proxy Statement will be made by
HealthWatch without Halis' prior consent (which shall not be unreasonably
withheld) and without providing Halis the opportunity to review and comment
thereon. HealthWatch will advise Halis promptly after it receives notice
thereof, of the time when the Form S-4 has become effective or any supplement or
amendment has been filed, the issuance of any stop order, the suspension of the
qualification of the HealthWatch Common Stock issuable in connection with the
Merger for offering or sale in any jurisdiction, or any request by the SEC for
amendment of the Joint Proxy Statement or the Form S-4 or comments thereon and
responses thereto or requests by the SEC for additional information. If at any
time prior to the Effective Time any information relating to HealthWatch or
Halis, or any of their respective affiliates, officers or directors, should be
discovered by HealthWatch or Halis which should be set forth in an amendment or
supplement to any of the Form S-4 or the Joint Proxy Statement, so that any of
such documents would not include any misstatement of a material fact or omit to
state any material fact necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading, the party which
discovers such information shall promptly notify the other parties hereto and an
appropriate amendment or  supplement describing such information shall be
promptly filed with the SEC and, to the extent required by law, disseminated to
the stockholders of HealthWatch and Halis.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 31

     (b) HealthWatch shall, as promptly as practicable after the Form S-4 is
declared effective under the Securities Act, duly give notice of, convene and
hold a meeting of its stockholders (the "HealthWatch Stockholders' Meeting") in
accordance with Minnesota law for the purpose of obtaining the HealthWatch
Stockholder Approval and shall, through its Board of Directors, recommend to its
stockholders the approval and adoption of this Agreement, the Merger and the
other transactions contemplated hereby.

     (c) Halis shall, as promptly as practicable after the Form S-4 is declared
effective under the Securities Act, duly give notice of, convene and hold a
meeting of its stockholders (the "Halis Stockholders' Meeting") in accordance
with the Georgia law for the purpose of obtaining the Halis Stockholder Approval
and shall, subject to the provisions of Section 4.2(b) hereof, through its Board
of Directors, recommend to its stockholders the approval and adoption of this
Agreement, the Merger and the other transactions contemplated hereby.

     (d) Halis and HealthWatch will use commercially reasonable efforts to hold
the HealthWatch Stockholders' Meeting and the Halis Stockholders' Meeting on the
same date and as soon as reasonably practicable after the date hereof, but not
later than September 30, 2000.

     (e) Each of HealthWatch's and Halis' obligations under this Section 5.1
shall at all times remain subject to the provisions of Section 4.2(c), in the
event that under the circumstances described therein, the Board of Directors of
Halis shall have made a Halis Subsequent Determination, as the case may be.

     SECTION 5.2 LETTERS OF HEALTHWATCH'S ACCOUNTANTS.  HealthWatch shall use
commercially reasonable efforts to cause to be delivered to Halis two letters
from HealthWatch's independent accountants, one dated as of the date the Form
S-4 is declared effective and one dated as of the Closing Date, each addressed
to Halis, in form and substance reasonably satisfactory to Halis and customary
in scope and substance for comfort letters delivered by independent public
accountants in connection with registration statements similar to the Form S-4.

     SECTION 5.3 LETTERS OF HALIS' ACCOUNTANTS.   Halis shall use commercially
reasonable efforts to cause to be delivered to HealthWatch two letters from
Halis' independent accountants, one dated as of the date the Form S-4 is
declared effective and one dated as of the Closing Date, each addressed to
HealthWatch, in form and substance reasonably satisfactory to HealthWatch and
customary in scope and substance for comfort letters delivered by independent
public accountants in connection with registration statements similar to the
Form S-4.

     SECTION 5.4 ACCESS TO INFORMATION; CONFIDENTIALITY. Subject to the
Confidentiality Agreement and subject to applicable law, each of HealthWatch and
Halis shall, and shall cause each of its respective subsidiaries to, afford to
the other party and to the officers, employees, accountants, counsel, financial
advisors and other representatives of such other party, reasonable access during
normal business hours during the period prior to the Effective Time to all their
respective properties, books, contracts, commitments, personnel and records
(provided that such access shall not interfere with the business or operations
of such party) and, during such period, each of HealthWatch and Halis shall, and
shall cause each of its respective subsidiaries to, furnish promptly to the
other party (a) a copy of each report, schedule, registration statement and
other document filed by it during such period pursuant to the requirements of
federal or state securities laws and (b) all other information concerning its
business, properties and personnel as such other
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 32
party may reasonably request. No review pursuant to this Section 5.4 shall
affect any representation or warranty given by the other party hereto. Each of
HealthWatch and Halis will hold, and will cause its respective officers,
employees, accountants, counsel, financial advisors and other representatives
and affiliates to hold, any nonpublic information in accordance with the terms
of the Confidentiality Agreements.

     SECTION 5.5 COMMERCIALLY REASONABLE EFFORTS.

     (a) Upon the terms and subject to the conditions set forth in this
Agreement, each of the parties agrees to use commercially reasonable efforts to
take, or cause to be taken, all actions, and to do, or cause to be done, and to
assist and cooperate with the other parties in doing, all things necessary,
proper or advisable to consummate and make effective, in the most expeditious
manner practicable, the Merger and the other transactions contemplated by this
Agreement, including (i) the obtaining of all necessary actions or nonactions,
waivers, consents and approvals from Governmental Entities and the making of all
necessary registrations and filings and the taking of all steps as may be
necessary to obtain an approval or waiver from, or to avoid an action or
proceeding by, any Governmental Entity (except obtaining a revenue ruling that
the Merger qualifies as a tax-free reorganization), (ii) the obtaining of all
necessary consents, approvals or waivers, and any necessary or appropriate
financing arrangements, from third parties, (iii) the defending of any lawsuits
or other legal proceedings, whether judicial or administrative, challenging this
Agreement or the consummation of the transactions contemplated by this
Agreement, including seeking to have any stay or temporary restraining order
entered by any court or other Governmental Entity vacated or reversed, and (iv)
the execution and delivery of any additional instruments necessary to consummate
the transactions contemplated by, and to fully carry out the purposes of, this
Agreement. Notwithstanding anything to the contrary in this Agreement, neither
Halis nor HealthWatch shall be required to hold separate (including by trust or
otherwise) or divest any of their respective businesses or assets, or enter into
any consent decree or other agreement that would restrict either Halis or
HealthWatch in the conduct of its business as heretofore conducted.

     (b) In connection with and without limiting the foregoing, HealthWatch and
Halis shall (i) take all action necessary to ensure that no state takeover
statute or similar statute or regulation is or becomes applicable to this
Agreement, or any of the transactions contemplated hereby and thereby and (ii)
if any state takeover statute or similar statute or regulation becomes
applicable to such agreements or transactions, take all action necessary to
ensure that such transactions may be consummated as promptly as practicable on
the terms contemplated by this Agreement and otherwise to minimize the effect of
such statute or regulation on the Merger and the other transactions contemplated
by this Agreement.

     SECTION 5.6 INDEMNIFICATION, EXCULPATION AND INSURANCE.

     (a) For a period of three (3) years from the Closing, HealthWatch agrees to
maintain in effect in accordance with their terms all rights to indemnification
and exculpation from liabilities for acts or omissions occurring at or prior to
the Effective Time existing as of the date of this Agreement in favor of the
current or former directors or officers of Halis and its subsidiaries as
provided in their respective articles of incorporation or by-laws (or comparable
organizational documents) and any indemnification agreements of Halis. In
addition, from and after the Effective Time, directors and officers of Halis who
become directors or officers of HealthWatch will be entitled to the same
indemnity rights and protections, and directors' and officers' liability
insurance, as are afforded from time to time to other directors and officers of
HealthWatch.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 33

     (b) In the event that HealthWatch or any of its successors or assigns (i)
consolidates with or merges into any other person and is not the continuing or
surviving corporation or entity of such consolidation or merger or (ii)
transfers or conveys all or substantially all of its properties and assets to
any person, then, and in each such case, proper provision will be made so that
the successors and assigns of HealthWatch assume the obligations set forth in
this Section 5.6.

     (c) The provisions of this Section 5.6 (i) are intended to be for the
benefit of, and will be enforceable by, each indemnified party, his or her heirs
and his or her representatives and (ii) are in addition to, and not in
substitution for, any other rights to indemnification or contribution that any
such person may have by contract or otherwise.

     SECTION 5.7 FEES AND EXPENSES.

     (a) Except as set forth in this Section 5.7 and in Section 7.2, all fees
and expenses incurred in connection with the Merger, this Agreement  and the
transactions contemplated by this Agreement shall be paid by the party incurring
such fees or expenses, whether or not the Merger is consummated, except that
each of Halis and HealthWatch shall bear and pay one-half of the costs and
expenses incurred in connection with the filing, printing and mailing of the
Form S-4 and the Joint Proxy Statement (including SEC filing fees).  In
addition, all transfer taxes (if any) incurred in connection with the Merger
arising on or after the Effective Time shall be borne by HealthWatch.

     SECTION 5.8 PUBLIC ANNOUNCEMENTS.

     Halis and HealthWatch will consult with each other before issuing, and
provide each other the opportunity to review, comment upon and concur with, and
use reasonable efforts to agree on, any press release or other public statements
with respect to the transactions contemplated by this Agreement, including the
Merger, and shall not issue any such press release or make any such public
statement prior to such consultation, except as either party may determine is
required by applicable law, court process or by obligations pursuant to any
listing agreement with any national securities exchange or stock market. The
parties agree that the initial press release to be issued with respect to the
transactions contemplated by this Agreement shall be in the form heretofore
agreed to by the parties.

     SECTION 5.9 AFFILIATES.  As soon as practicable after the date hereof,
Halis shall deliver to HealthWatch a letter identifying all persons who may be
deemed to be, at the time this Agreement is submitted for adoption by the
stockholders of Halis, "affiliates" of Halis for purposes of Rule 145 under the
Securities Act.  Halis shall use commercially reasonable efforts to cause each
person identified on such list to deliver to HealthWatch on or before the date
immediately preceding the date of filing the Form S-4, written agreements
substantially in the forms attached as Exhibit  C hereto, and in the event any
other person becomes an affiliate of Halis thereafter to cause such person to
deliver such an agreement to HealthWatch as soon as practicable but in any event
at Closing.

     SECTION 5.10 NASDAQ. HealthWatch shall use commercially reasonable
efforts to cause the HealthWatch Common Stock issuable under Article II to be
approved for listing on Nasdaq SmallCap Market, subject to official notice of
issuance, as promptly as practicable after the date hereof, and in any event
prior to the Effective Time.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 34

     SECTION 5.11 TAX TREATMENT. Each of Halis and HealthWatch shall use
commercially reasonable efforts to cause the Merger to qualify as a
reorganization under the provisions of Section 368 of the Code and to obtain the
opinions of counsel referred to in Section 6.1(g). The parties will characterize
the Merger as such a reorganization for purposes of all tax returns and other
filings.

     SECTION 5.12 EMPLOYEE BENEFITS. Each of Halis and HealthWatch agrees to
provide immediately following the Effective Time employee benefits and
compensation arrangements for all their respective employees, at a level no less
favorable in the aggregate than those provided for such employees immediately
prior to the Effective Time, subject to later amendment or other alteration as
may be directed by the Board of Directors of HealthWatch subsequent to the
Effective Time.

     SECTION 5.13 LOCK-UP.   Substantial Halis Stockholders (defined as
directors, officers and Halis Shareholders owning 5% or more of Halis Common
Stock) and Affiliates will be required to agree not to sell, transfer or
otherwise dispose of any HealthWatch Common Stock prior to March 31, 2001 (the
"Lockup Period"); if HealthWatch undertakes a public offering within the Lockup
Period, Halis Stockholders shall agree not to sell, transfer or otherwise
dispose of the HealthWatch Common Stock for such period of time after completion
of such public offering (not to exceed one year).

                                  ARTICLE VI
                             CONDITIONS PRECEDENT

     SECTION 6.1 CONDITIONS TO EACH PARTY'S OBLIGATION TO EFFECT THE MERGER. The
respective obligation of each party to effect the Merger is subject to the
satisfaction or waiver on or prior to the Closing Date of the following
conditions:

     (a) STOCKHOLDER APPROVALS. Each of the HealthWatch Stockholder Approval and
the Halis Stockholder Approval shall have been obtained.

     (b) GOVERNMENTAL, REGULATORY AND OTHER APPROVALS. (i) All consents,
approvals and actions of, filings with and notices to any Governmental Entity
required of HealthWatch, Halis or any of their subsidiaries to consummate the
Merger and the other transactions contemplated hereby (together with the matters
contemplated by Section 6.1(b), the "Requisite Regulatory Approvals") shall have
been obtained and (ii) except as would not have a material adverse effect on any
of HealthWatch, Halis or the Surviving Corporation, the consents and approvals
set forth in Section 3.1(d) of the HealthWatch Disclosure Schedule and Section
3.2(d) of the Halis Disclosure Schedule shall have been obtained or shall no
longer be required.

     (c) NO INJUNCTIONS OR RESTRAINTS. No judgment, order, decree, statute, law,
ordinance, rule or regulation, entered, enacted, promulgated, enforced or issued
by any court or other Governmental Entity of competent jurisdiction or other
legal restraint or prohibition (collectively, "Restraints") shall be in effect
(i) preventing the consummation of the Merger, or (ii) which otherwise is
reasonably likely to have a material adverse effect on HealthWatch or Halis, as
applicable; provided, however, that each of the parties shall have used
commercially reasonable efforts to prevent the entry of any such Restraints and
to appeal as promptly as possible any such Restraints that may be entered.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 35

     (d) FORM S-4. The Form S-4 shall have become effective under the
Securities Act prior to the mailing of the Joint Proxy Statement by each of
HealthWatch and Halis to their respective stockholders and no stop order or
proceedings seeking a stop order shall be threatened by the SEC or shall have
been initiated by the SEC.

     (e) NASDAQ LISTINGS. The shares of HealthWatch Common Stock issuable to
Halis' stockholders as contemplated by Article II shall have been approved for
listing on Nasdaq SmallCap Market, subject to official notice of issuance.

     (f) TAX OPINIONS. Halis shall have received from Gomel & Davis, L.L.P.,
counsel to Halis, and HealthWatch shall have received from Gambrell & Stolz,
L.L.P., counsel to HealthWatch, an opinion, dated as of the date that the
Registration Statement is declared effective, to the effect that the Merger will
constitute a "reorganization" within the meaning of Section 368(a) of the Code,
and such opinions shall not have been withdrawn or materially modified as of the
Closing Date. In rendering such opinions, each of counsel for Halis and
HealthWatch shall have been entitled to receive and rely upon representations of
fact contained in certificates of officers of Halis and HealthWatch, which
representations shall be in form and substance satisfactory to such counsel.

     (g) OPINION OF FINANCIAL ADVISORS. HealthWatch shall receive an opinion
from a financial advisor, to be engaged at a later date, in HealthWatch's sole
discretion, to the effect that, as of the date of such opinion, the Merger
Consideration and Exchange Ratio for the conversion of Halis Common Stock into
HealthWatch Common Stock is fair from a financial point of view to the
stockholders of HealthWatch, a signed copy of which opinion shall be delivered
to Halis.  In the event HealthWatch is unable to obtain this opinion, the
termination fee set forth in Section 7.2 shall not be paid by HealthWatch to
Halis.

     (h) OPINION OF FINANCIAL ADVISORS. Halis shall receive the opinion of New
York Capital Corporation, to the effect that, as of the date of such opinion,
the Exchange Ratio for the conversion of HealthWatch Common Stock into Halis
Common Stock is fair from a financial point of view to the stockholders of
Halis, a signed copy of which opinion shall be delivered to HealthWatch.  In the
event Halis is unable to obtain this opinion, the termination fee set forth in
Section 7.2 shall not be paid by Halis to HealthWatch.

     (i) LOCKUP AGREEMENTS. Halis obtains from all Substantial Halis
Stockholders and Affiliates a fully executed Lock-up Agreement as provided for
in Section 5.13.

     SECTION 6.2 CONDITIONS TO OBLIGATIONS OF HALIS. The obligation of Halis to
effect the Merger is further subject to satisfaction or waiver of the following
conditions:

     (a) REPRESENTATIONS AND WARRANTIES. The representations and warranties of
HealthWatch set forth herein shall be true and correct both when made and at and
as of the Closing Date, as if made at and as of such time (except to the extent
expressly made as of an earlier date, in which case as of such date), except
where the failure of such representations and warranties to be so true and
correct (without giving effect to any limitation as to "materiality" or
"material adverse effect" set forth therein) does not have, and is not likely to
have, individually or in the aggregate, a material adverse effect on
HealthWatch.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 36

     (b) PERFORMANCE OF OBLIGATIONS OF HEALTHWATCH. HealthWatch shall have
performed in all material respects all obligations required to be performed by
it under this Agreement at or prior to the Closing Date.

     (c) NO MATERIAL ADVERSE CHANGE. At any time after the date of this
Agreement there shall not have occurred any material adverse change relating to
HealthWatch.

     SECTION 6.3 CONDITIONS TO OBLIGATIONS OF HEALTHWATCH. The obligation of
HealthWatch to effect the Merger is further subject to satisfaction or waiver of
the  following conditions:

     (a) REPRESENTATIONS AND WARRANTIES. The representations and warranties of
Halis set forth herein shall be true and correct both when made and at and as of
the Closing Date, as if made at and as of such time (except to the extent
expressly made as of an earlier date, in which case as of such date), except
where the failure of such representations and warranties to be so true and
correct (without giving effect to any limitation as to "materiality," or
"material adverse effect" set forth therein) does not have, and is not likely to
have, individually or in the aggregate, a material adverse effect on Halis.

     (b) PERFORMANCE OF OBLIGATIONS OF HALIS. Halis shall have performed in all
material respects all obligations required to be performed by it under this
Agreement at or prior to the Closing Date.

     (c) NO MATERIAL ADVERSE CHANGE. At any time after the date of this
Agreement there shall not have occurred any material adverse change relating to
Halis.

                                  ARTICLE VII
                       TERMINATION, AMENDMENT AND WAIVER

     SECTION 7.1 TERMINATION. This Agreement may be terminated at any time prior
to the Effective Time, and (except in the case of 7.1(e) or 7.1(f)) whether
before or after the HealthWatch Stockholder Approval or the Halis Stockholder
Approval:

     (a) by mutual written consent of Halis and HealthWatch, if the Board of
Directors of each so determines by a vote of a majority of its entire Board;

     (b) by either the Board of Directors of Halis or the Board of Directors of
HealthWatch: (i) if the Merger shall not have been consummated by September 30,
2000, unless such termination right has been expressly restricted in writing by
the Board of Directors of Halis or HealthWatch, as the case may be; provided,
however, that the right to terminate this Agreement pursuant to this Section
7.1(b)(i) shall not be available to any party whose failure to perform any of
its obligations under this Agreement results in the failure of the Merger to be
consummated by such time; (ii) if the HealthWatch Stockholder Approval shall not
have been obtained at a HealthWatch Stockholders' Meeting duly convened therefor
or at any adjournment or postponement thereof; (iii) if the Halis Stockholder
Approval shall not have been obtained at a Halis Stockholders' Meeting duly
convened therefor or at any adjournment or postponement thereof; (iv) if any
Restraint having any of the effects set forth in Section 6.1(d) shall be in
effect and shall have become final and nonappealable, or if any Governmental
Entity that must grant a Requisite Regulatory Approval has denied approval of
the Merger and such denial has become final and nonappealable; provided, that
the party seeking to terminate this Agreement
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 37

pursuant to this Section 7.1(b)(iv) shall have used commercially reasonable
efforts to prevent the entry of and to remove such Restraint or to obtain such
Requisite Regulatory Approval, as the case may be; or (v) if the financial
advisor opinion required by Section 6.1(g) or (h) is not received because the
advisor indicates that it does not deem the transaction fair as stated in such
Sections.

     (c) by the Board of Directors of Halis (provided that Halis is not then in
material breach of any representation, warranty, covenant or other agreement
contained herein), if HealthWatch shall have breached or failed to perform any
of its representations, warranties, covenants or other agreements contained in
this Agreement, which breach or failure to perform (A) would give rise to the
failure of a condition set forth in Section 6.2(a) or (b), and (B) is incapable
of being cured by HealthWatch or is not cured within 30 days of written notice
thereof;

     (d) by the Board of Directors of HealthWatch (provided that HealthWatch is
not then in material breach of any representation, warranty, covenant or other
agreement contained herein), if Halis shall have breached or failed to perform
in any material respect any of its representations, warranties, covenants or
other agreements contained in this Agreement, which breach or failure to
perform (A) would give rise to the failure of a condition set forth in Section
6.3(a) or (b), and (B) is incapable of being cured by Halis or is not cured
within 30 days of written notice thereof;

     (e) by the Board of Directors of Halis, at any time prior to the
HealthWatch Stockholders' Meeting, if the HealthWatch Board of Directors shall
have (A) failed to include in the Joint Proxy Statement to the HealthWatch
Stockholders, its recommendation without modification or qualification that such
stockholders approve this Agreement and the transactions contemplated hereby, or
(B) subsequently withdrawn such recommendation or (C) modified or qualified such
recommendation in a manner adverse to the interests of Halis;

     (f) by the Board of Directors of HealthWatch, at any time prior to the
Halis Stockholders' Meeting, if the Halis Board of Directors shall have (A)
failed to include in the Joint Proxy Statement to the Halis Stockholders, its
recommendation without modification or qualification that such stockholders
approve this Agreement and the transaction contemplated hereby, (B) subsequently
withdrawn such recommendation or (C) modified or qualified such recommendation
in a manner adverse to the interests of HealthWatch; or

     (g) by Halis if the Board of Directors of HealthWatch shall have failed to
take any of the actions contemplated by Section 5.1 as a result of the exercise
of its rights under Section 5.1(e); or

     (h) by HealthWatch if the Board of Directors of Halis shall have failed to
take any of the actions contemplated by Section 5.1 as a result of the exercise
of its rights under Section 5.1(e).

     SECTION 7.2 EFFECT OF TERMINATION.

     (a) In the event of termination of this Agreement as provided in Section
7.1 hereof, and subject to the provisions of Section 8.1 hereof, this Agreement
shall forthwith become void and there shall be no liability on the part of any
of the parties, except (i) as set forth in this Section 7.2 and in Sections 5.4,
5.7, 3.1(n) and 3.2(n) hereof, and (ii) nothing herein shall relieve any party
from liability for any willful breach hereof.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 38

     (b) If this Agreement is terminated (i) by Halis pursuant to Section 7.1(e)
hereof, (ii) by Halis or HealthWatch pursuant to Section 7.1(b)(ii) hereof
because of the failure to obtain the required approval from the HealthWatch
stockholders and at the time of such termination or prior to the meeting of
HealthWatch's or (iii) by Halis as a result of HealthWatch's material breach of
Section  5.1 hereof which is not cured within 30 days after notice thereof to
HealthWatch, HealthWatch shall pay to Halis a termination fee of Five Hundred
Thousand Dollars ($500,000.00) (the "HealthWatch Termination Fee").

     (c) If this Agreement is terminated (i) by HealthWatch pursuant to Sections
7.1(f) hereof, (ii) by Halis or HealthWatch pursuant to Section 7.1(b)(iii)
hereof because of the failure to obtain the required approval from the Halis
stockholders and at the time of such termination or prior to the meeting of
Halis' stockholders there shall have been an offer or proposal for, an
announcement of any intention with respect to (including, without limitation,
the filing of a statement of beneficial ownership on Schedule 13D discussing the
possibility of or reserving the right to engage in), any agreement with respect
to, a transaction that would constitute an Alternative Transaction (as defined
in Section 4.2(b) hereof, except that for purposes of clause (i) of such
definition, the applicable percentage shall be fifty percent (50%) involving
Halis or any of the Halis Subsidiaries (whether or not such offer, proposal,
announcement or agreement shall have been rejected or shall have been withdrawn
prior to the time of such termination or of the meeting), (iii) by HealthWatch
as a result of Halis' material breach of Section 4.2 or 5.1 hereof which, in the
case of Section 5.1 only, is not cured within 30 days after notice thereof to
Halis or (iv) by HealthWatch pursuant to Section 7.1(h) hereof, Halis shall pay
to HealthWatch a termination fee of Five Hundred Thousand Dollars ($500,000.00)
(the "Halis Termination Fee").

     (d) Each Termination Fee payable under Sections 7.2(b) and (c) above shall
be payable in cash, payable no later than one business day following the
delivery of notice of termination to the other party.

     (e) Halis and HealthWatch agree that the agreements contained in Sections
7.2(b) and (c) above are an integral part of the transaction contemplated by
this Agreement and constitute liquidated damages and not a penalty. If one party
fails to promptly pay to the other any fee due under such Sections 7.2(b) and
(c), the defaulting party shall pay the costs and expenses (including legal fees
and expenses) in connection with any action, including the filing of any lawsuit
or other legal action, taken to collect payment.

     SECTION 7.3 AMENDMENT. Subject to compliance with applicable law, this
Agreement may be amended by the parties at any time before or after the
HealthWatch Stockholder Approval or the Halis Stockholder Approval; provided,
however, that after any such approval, there may not be, without further
approval of such the stockholders of HealthWatch (in the case of the HealthWatch
Stockholders Approval) and the stockholders of Halis (in the case of the Halis
Stockholders Approval), any amendment of this Agreement that changes the amount
or the form of the consideration to be delivered to the holders of HealthWatch
Common Stock hereunder, or which by law otherwise expressly requires the further
approval of such stockholders. This Agreement may not be amended except by an
instrument in writing signed on behalf of each of the parties hereto and duly
approved by the parties' respective Boards of Directors or a duly designated
committee thereof.

     SECTION 7.4 EXTENSION; WAIVER. At any time prior to the Effective Time, a
party may, subject to the proviso of Section 7.3 (and for this purpose treating
any waiver referred to below as an amendment), (a) extend the time for the
performance of any of the obligations or other acts of the other parties, (b)
waive any inaccuracies in the representations and warranties of the other
parties contained in this Agreement
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 39

or in any document delivered pursuant to this Agreement or (c) waive compliance
by the other party with any of the agreements or conditions contained in this
Agreement. Any agreement on the part of a party to any such extension or waiver
shall be valid only if set forth in an instrument in writing signed on behalf of
such party. Any extension or waiver given in compliance with this Section 7.4 or
failure to insist on strict compliance with an obligation, covenant, agreement
or condition shall not operate as a waiver of, or estoppel with respect to, any
subsequent or other failure.

                                 ARTICLE VIII
                              GENERAL PROVISIONS

     SECTION 8.1 NONSURVIVAL OF REPRESENTATIONS AND WARRANTIES. None of the
representations and warranties in this Agreement or in any instrument delivered
pursuant to this Agreement shall survive the Effective Time. This Section 8.1
shall not limit any covenant or agreement of the parties which by its terms
contemplates performance after the Effective Time.

     SECTION 8.2 NOTICES. All notices, requests, claims, demands and other
communications under this Agreement shall be in writing and shall be deemed
given if delivered personally, telecopied (which is confirmed) or sent by
overnight courier (providing proof of delivery) to the parties at the following
addresses (or at such other address for a party as shall be specified by like
notice):

     (a) if to Halis, to:       7 Piedmont Center
                                Suite 300
                                3525 Piedmont Road
                                Atlanta, Georgia 30305

     with a copy to:            Gomel & Davis, L.L.P.
                                285 Peachtree Center Avenue, Suite 700
                                Atlanta, Georgia 30303
                                Facsimile No: 404-524-4755
                                Attention: Jed S. Beardsley, Esq.

     (b) if to HealthWatch, to: 7 Piedmont Center
                                Suite 30
                                3525 Piedmont Road
                                Atlanta, Georgia 30305

     with a copy to:            Gambrell & Stolz, L.L.P.
                                Suntrust Plaza, Suite 4300
                                303 Peachtree Street, N.E.
                                Atlanta, GA 30308-3252
                                Facsimile No.: 404-221-6501
                                Attention: Michael M. Smith, Esq.

     SECTION 8.3 DEFINITIONS. For purposes of this Agreement:
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 40

     (a) except for purposes of Section 5.10, an "affiliate" of any person means
another person that directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with, such first person,
where "control" means the possession, directly or indirectly, of the power to
direct or cause the direction of the management policies of a person, whether
through the ownership of voting securities, by contract, as trustee or executor,
or otherwise;

     (b) "material adverse change" or "material adverse effect" means, when used
in connection with HealthWatch or Halis, any change, effect, event, occurrence
or state of facts that is or could reasonably be expected to be materially
adverse to the business, financial condition or results of operations of such
party and its subsidiaries taken as a whole, it being understood that none of
the following shall be deemed by itself or by themselves, either alone or in
combination, to constitute a material adverse effect: (i) a change in the market
price or trading volume of Halis or HealthWatch Common Stock, as the case maybe
or (ii) conditions affecting the U.S. economy as a whole;

     (c) "Nasdaq" means the National Association of Securities Dealers Automated
Quotation.

     (d) "person" means an individual, corporation, partnership, limited
liability company, joint venture, association, trust, unincorporated
organization or other entity;

     (e) a "subsidiary" of any person means another person, an amount of the
voting securities, other voting ownership or voting partnership interests of
which is sufficient to elect at least a majority of its Board of Directors or
other governing body (or, if there are no such voting interests, 50% or more of
the equity interests of which) is owned directly or indirectly by such first
person; and

     (f) "knowledge" of any person which is not an individual means the
knowledge of such person's executive officers or senior management of such
person's operating divisions and segments.

     SECTION 8.4 INTERPRETATION. When a reference is made in this Agreement to
an Article, Section or Exhibit, such reference shall be to an Article or Section
of, or an Exhibit to, this Agreement unless otherwise indicated. Whenever the
words "include," "includes" or "including" are used in this Agreement, they
shall be deemed to be followed by the words "without limitation." The words
"hereof," "herein" and "hereunder" and words of similar import when used in this
Agreement shall refer to this Agreement as a whole and not to any particular
provision of this Agreement. All terms defined in this Agreement shall have the
defined meanings when used in any certificate or other document made or
delivered pursuant hereto unless otherwise defined therein. The definitions
contained in this Agreement are applicable to the singular as well as the plural
forms of such terms and to the masculine as well as to the feminine and neuter
genders of such term. Any agreement, instrument or statute defined or referred
to herein or in any agreement or instrument that is referred to herein means
such agreement, instrument or statute as from time to time amended, modified or
supplemented, including (in the case of agreements or instruments) by waiver or
consent and (in the case of statutes) by succession of comparable successor
statutes and references to all attachments thereto and instruments incorporated
therein. References to a person are also to its permitted successors and
assigns.

     SECTION 8.5 COUNTERPARTS. This Agreement may be executed in one or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been signed by each of
the parties and delivered to the other parties.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 41

     SECTION 8.6 ENTIRE AGREEMENT; NO THIRD-PARTY BENEFICIARIES. This Agreement
(including the documents and instruments referred to herein) and the
Confidentiality Agreement (a) constitute the entire agreement, and supersede all
prior agreements and understandings, both written and oral, between the parties
with respect to the subject matter of this Agreement and (b) except for the
provisions of Section 5.6, are not intended to confer upon any person other than
the parties any rights or remedies.

     SECTION 8.7 GOVERNING LAW. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of Georgia, regardless of
the laws that might otherwise govern under applicable principles of conflict of
laws thereof.

     SECTION 8.8 ASSIGNMENT. Neither this Agreement nor any of the rights,
interests or obligations under this Agreement shall be assigned, in whole or in
part, by operation of law or otherwise by either of the parties hereto without
the prior written consent of the other party. Any assignment in violation of the
preceding sentence shall be void. Subject to the preceding two sentences, this
Agreement will be binding upon, inure to the benefit of, and be enforceable by,
the parties and their respective successors and assigns.

     SECTION 8.9 CONSENT TO JURISDICTION. Each of the parties hereto (a)
consents to submit itself to the personal jurisdiction of any federal court
located in the State of Georgia or any Georgia state court in the event any
dispute arises out of this Agreement or any of the transactions contemplated by
this Agreement, (b) agrees that it will not attempt to deny or defeat such
personal jurisdiction by motion or other request for leave from any such court
and (c) agrees that it will not bring any action relating to this Agreement or
any of the transactions contemplated by this Agreement in any court other than a
federal court sitting in the State of Georgia or a Georgia state court.

     SECTION 8.10 HEADINGS, ETC. The headings and table of contents contained in
this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement.

     SECTION 8.11 SEVERABILITY. If any term or other provision of this Agreement
is invalid, illegal or incapable of being enforced by any rule of law or public
policy, all other conditions and provisions of this Agreement shall nevertheless
remain in full force and effect, insofar as the foregoing can be accomplished
without materially affecting the economic benefits anticipated by the parties to
this Agreement. Upon such determination that any term or other provision is
invalid, illegal or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the parties as closely as possible to the fullest extent permitted by
applicable law in an acceptable manner to the end that the transactions
contemplated hereby are fulfilled to the extent possible.

     SECTION 8.12 DISCLOSURE SCHEDULES AND EXHIBITS. The HealthWatch Disclosure
Schedules shall be delivered to Halis and the Halis Disclosure Schedules shall
be delivered to HealthWatch on or before July 15, 2000; however, the
capitalization schedule of each party is attached hereto.
<PAGE>

                                                    AGREEMENT AND PLAN OF MERGER
                                                               HEALTHWATCH, INC.
                                                                         Page 42

     IN WITNESS WHEREOF, Halis, HealthWatch and Merger Sub have caused this
Agreement to be signed by their respective officers thereunto duly authorized,
all as of the date first written above.

                                        HALIS, INC.

                                        /s/ Joel R. Greenspan
                                        ----------------------------
                                        By: Joel R. Greenspan
                                        Its: Member of the Board of Directors

                                        /s/ Marilyn May
                                        ----------------------------
                                        Attest: Marilyn May
                                        Its: Assistant Secretary

                                            [CORPORATE SEAL]

                                        HEALTHWATCH, INC.

                                        /s/ Robert Tucker
                                        ----------------------------
                                        By: Robert Tucker
                                        Its: Member of the Board of Directors

                                        /s/ Marilyn May
                                        ----------------------------
                                        Attest: Marilyn May
                                        Its: Assistant Secretary

                                            [CORPORATE SEAL]

                                        HEALTHWATCH MERGER SUB, INC.

                                        /s/ Paul W. Harrison
                                        ----------------------------
                                        By: Paul W. Harrison
                                        Its: President

                                        /s/ Marilyn May
                                        ----------------------------
                                        Attest: Marilyn May
                                        Its: Assistant Secretary

                                            [CORPORATE SEAL]<PAGE>

                                                                    Exhibit 10.7
Amendment to the Business Collaboration Agreement between HealthWatch, Inc. and
Halis, Inc.

                               AMENDMENT TO THE
                               -----------------
                       BUSINESS COLLABORATION AGREEMENT
                       --------------------------------

     This AMENDMENT TO THE BUSINESS COLLABORATION AGREEMENT ("Amendment"), dated
as of September 20, 2000 is made and entered into by and among (i) Halis, Inc.
("HALIS"), a Georgia corporation and (ii) HealthWatch, Inc. ("HealthWatch"), a
Minnesota corporation.

     WHEREAS, HALIS and HealthWatch have entered into that certain Business
Collaboration Agreement dated as of October 10, 1997 (the Agreement") to provide
both parties with access to the other party's software products; and

     WHEREAS, HALIS and HealthWatch both desire to extend the term of the
Agreement and adjust the royalty fees contained therein.

     THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which hereby are acknowledged, the parties, intending to be legally bound, do
hereby agree as follows:

     1.  Section 2 of the Agreement shall be deleted in its entirety and
replaced with the following:

     "2.1  HealthWatch License. HALIS grants to HealthWatch a non-exclusive
           -------------------
     right to distribute, market, sub-license, and private label HALIS software
     products. HealthWatch agrees to pay HALIS, a $50,000 per month
     collaboration fee.  HealthWatch will share revenues received from such
     activities on a 60/40 basis, whereby 60% will be allocated to HealthWatch
     and 40% will be allocated to HALIS.  All collaboration fees paid to HALIS
     for the life of this agreement will be cumulated in the form of a credit to
     be applied to the revenue sharing amounts owed to HALIS by HealthWatch.
     Revenue sharing amounts will be determined on a quarterly basis, and any
     amount owed, net of the collaboration fee credits, will be paid to HALIS
     within 30 days after the conclusion of each quarter.  HALIS shall (i)
     provide support to HealthWatch for the HALIS software products and
     reasonable product enhancements as part of product release updates and (ii)
     accept and review input from HealthWatch with regard to reasonable product
     enhancement requests to be included in future product release updates.
     HealthWatch shall have the option to terminate its license granted under
     this Section 2.1 on or after October 1, 2001 upon 90 days prior written
     notice to Halis (provided all net revenue sharing fees are paid and
     current), in which event its obligation to pay the $50,000 monthly
     collaboration fee shall terminate.  Revenue sharing shall continue with
     respect to any sub-license previously granted by
<PAGE>

     HealthWatch under this Agreement. Previously paid collaboration fees shall
     continue to operate as a credit against amounts owed to HALIS. HALIS shall
     continue to provide support required under this Agreement for all
     outstanding product licenses issued by HealthWatch after such termination.
     However, should HealthWatch exercise its option to terminate the monthly
     collaboration fee, HALIS shall have the option to terminate its support
     obligations under this Section 2.1 in exchange for waiving all unearned
     future revenue sharing payments due to HALIS under this Section 2.1.

     2.2.  HALIS License. HealthWatch grants to HALIS a non-exclusive right to
           -------------
     market, distribute, sub-license and private label HealthWatch's information
     technology software. HALIS will share revenues received from such sales or
     sub-licensing of the HealthWatch software technology on a 60/40 basis,
     whereby 60% will be allocated to HALIS and 40% will be allocated to
     HealthWatch. The provisions of the Business Collaboration Agreement
     associated with this paragraph 2.2 will remain in effect for the term of
     the Agreement. All revenue sharing shall be paid to HealthWatch on a
     quarterly basis within 30 days after the conclusion of each quarter.

     2.3  Set-Offs Permitted.  HealthWatch and HALIS both agree that either
          ------------------
     party shall be permitted to deduct any amounts payable under this Agreement
     and apply such payment to any undisputed amounts due and payable from the
     other party as a result of fees payable under this Agreement, cost sharing
     arrangements between the parties or any other similar arrangements."

     2.  Section 6 of the Agreement shall be deleted in its entirety and
replaced with the following:

     "6.  Term.  The term of this Agreement shall expire on September 20, 2005,
          ----
     and shall be automatically extended for additional one-year terms, unless
     terminated by  one of the parties by giving a written notice to the other
     party ninety days prior to the end of the original term or the additional
     one year renewal terms."

     3.  Except as modified by this Amendment, all terms and conditions of the
Agreement are hereby reaffirmed.
<PAGE>

     IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the
effective date mentioned above.

HEALTHWATCH, INC.                               HALIS, INC.

/s/ David Engert                                /s/ Paul W. Harrison
----------------------------                    ----------------------------
By:  David Engert                               By: Paul W. Harrison
Its: Chief Operating Officer                    Its: President
Date: September 20, 2000                        Date: September 20, 2000

/s/ Tom Ridenour                                /s/ Joel Greenspan
----------------------------                    ----------------------------
By: Tom Ridenour                                By: Joel Greenspan
Its: Chief Financial Officer                    Its: Director
Date: September 20, 2000                        Date: September 20, 2000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]